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CHAPTER 1 INTRODUCTION 
 
1.1 Currently Licensed Vaccines 
Since Edward Jenner’s discovery that cowpox could prevent human from the threat 
of smallpox infection, vaccines have become the most important and successful strategy 
to protect against infectious diseases.1-3 Currently, there are several types of licensed 
vaccines available, including attenuated or killed pathogens, toxoids, proteins or 
polysaccharides from those pathogens, and so on (Table 1.1).4  
Table 1.1 Examples of licensed vaccines1,4 
Vaccine type Vaccine examples 
Live mycob Tuberculosis 
Live attenuated Influenza (intranasal), Measles, Mumps, Polio (Sabin), Rotavirus, Rubella, Varicella, 
Yellow Fever 
Killed Hepatitis A, Pertussis (whole cell), Polio (Salk), Rabies,  
Killed, subunit Influenza 
Toxoid Diphtheria toxoid, Tetanus toxoid,  
Protein Hepatitis B, Pertussis (acellular),  
PS Hib PS, Meningococcal PS, Pneumococcal PS, Typhoid PS 
PS-protein Hib glycoconjugates, Meningococcal conjugates, Pneumococcal conjugates 
Virus-like-
particle 
Papillomavirus 
Hib: Haemophilus influenzae type B; PS: polysaccharide  
Vaccines derived from bacterial and viral particles or subunits, such as influenza 
vaccine5,6, Bacillus Calmette-Guerin (BCG)7 and measles, and from attenuated or killed 
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pathogens are relatively easily accessed and developed.8 Hence, once an epidemic 
surges and the pathogen of the disease is found, it is theoretically quick to design a 
vaccine based on the pathogen itself. Currently, most of the successful vaccines in clinical 
applications are developed empirically. For example, the seasonal influenza vaccines are 
always developed based on the specific influenza virus components which vary year to 
year.5,6  
Despite the great success of whole cell and subunit/component-based vaccines, 
there are still concerns or issues about them. First, the number of vaccines is still limited, 
and there are still many diseases that have not been covered.1,9 Second, many of the 
vaccines have limited immunological efficacy or are only effective in certain populations 
not including young children who need more protection against pathogens.10-12 For 
example, to control the spread of typhoid fever by routine vaccination, three licensed 
vaccines, parenteral inactivated whole-cell vaccine, oral attenuated S. typhi Ty21a 
vaccine, and parenteral Vi polysaccharide vaccine, confer only about 70% protection in 
older children and adults and do not protect young children.11,13 safety issues and the 
difficulties in quality control are other important issues associated with these vaccines. 
Potential incomplete attenuation and contamination caused by pathogenic residuals are 
big impediments to vaccine safety.14,15 
In recent decades, vaccines derived from some specific antigenic components of 
pathogens, including both proteins or polysaccharide (PS), have been developed, such 
as vaccines against Hib12,16-19, N. meningitidis10,20 and S. pneumoniae21-24. Regarding 
these vaccines, the antigenic components are structurally defined and can be easily 
accessible from cultured bacteria in purified form. Therefore, these vaccines play an 
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important role in the study of vaccine immunology and the interactions between antigens 
and the immune systems. Understanding the mechanism of vaccines and immunological 
interactions may help us design and optimize vaccines that can elicit more effective and 
long-term immunity.25  
Proteins and carbohydrates of pathogens are two major components that can be 
attractive targets for vaccine development. Pathogen proteins can often elicit strong and 
T cell-dependent immune responses, so they have been useful and popular targets for 
vaccine design. On the other hand, carbohydrates alone typically only introduce short-
term and T cell-independent immunity,26-29 especially in infants and children. Therefore, 
pathogen polysaccharides have been mainly used as vaccines for adults. To overcome 
this problem, carbohydrates have been coupled with carrier proteins to form conjugate 
vaccines.22 In this way, the immune response induced against carbohydrate antigens can 
be switched to T cell-dependent immunity which is more potent and functional. In addition, 
the immune responses induced by conjugate vaccine have long-term effects and better 
immunological activities.23,24 In the meantime, carbohydrates are exposed on the cell 
surface, making them easily recognized by and interacting with the immune system.30 
Consequently, the unique carbohydrates as antigens of both pathogen and cancer cells 
have become particularly important targets for various immune studies and for vaccine 
design.1,30 As the main topic of the present dissertation, carbohydrate-based vaccines will 
be the focus of the introduction.   
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1.2 Carbohydrate-Based Vaccines 
The unique glycans expressed by pathogens, including bacteria, parasites, fungi 
and viruses, as well as the abnormal glycans on tumor cells, are very attractive markers 
for the design and development of novel carbohydrate-based vaccines.1,31-33 First, the 
glycans expressed by pathogens or the abnormal glycans expressed by tumors often 
have distinctive chemical structures and are exposed on the cell surface, thus they are 
easy targets as antigens for the immune system.1,10,34-37 Second, carbohydrates are 
typically highly conserved and are often the most abundant antigens on the cell surface. 
Consequently, development of carbohydrate–based vaccines against various diseases 
(Figure 1.1) has been a hot area in recent decades, and many new and highly effective 
vaccines have been developed.1,31,38 For example, as mentioned above, current licensed 
vaccines against typhoid fever confer only about 70% protection in older children and 
adults and have no protection to young children.11,13 To deal with the issue, Lin et al 
developed a new conjugate vaccine based on the capsular polysaccharide of Salmonella 
typhi, which has been demonstrated to be safe and strongly immunogenic and have 
shown more that 90% efficacy in children two to five years old.11  
Despite that some specific carbohydrates on the cell surface can be potentially 
ideal antigens for the development of vaccines, they still have problems and limitations. 
Most importantly, carbohydrates alone usually have low immunogenicity and are T cell-
independent antigens,30,31 thus even if they are immunogenic, they typically elicit T cell-
independent immune responses and fail to activate T cell immunity.26-29 As a result, the 
inducing immune responses are often weaker and shorter antibody responses lacking 
necessary immune memory.30,31 Moreover, carbohydrates alone usually cannot induce 
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robust immune responses in children under 5 years old. Therefore, although a number of 
antibacterial vaccines made of pure polysaccharides have been developed, they are only 
used in adults in clinic. 
 
Figure 1.1 Carbohydrate antigens have been employed for various vaccine designs 
A widely adopted strategy that has been employed to overcome the problem of 
low immunogenicity of carbohydrate antigens is to link them to a large, immunologically 
active protein carrier to form glycoprotein conjugates. This would not only improve the 
immunogenicity of carbohydrates but also switch them to T cell-dependent antigens and 
formulate functional vaccines. In this way, many effective carbohydrate-based vaccines 
have been developed, which will be discussed in detail in the following sections. 
However, polysaccharide-protein conjugates as vaccines have complex structure 
and are difficult to analyze and control in terms of quality and purity.39-42 To overcome this 
problem, in recent years, new vaccine designs and strategies have been explored, such 
as conjugate vaccines derived from chemical synthetic carbohydrate antigens that are 
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homogeneous and fully synthetic conjugate vaccines with well-defined structure. These 
vaccines may provide consistent quality as well as improved safety.1,38 To meet this 
demand, new carrier molecules, in addition to proteins, have been exploited for the 
development of synthetic glycoconjugate vaccines.42-45 
 
1.3 Carbohydrate-Based Cancer Vaccines 
1.3.1 Tumor-associated carbohydrate antigens  
The association of abnormal glycosylations with tumor progression was first 
discovered by Meezan et al. in 1969 with the demonstration that many glycans on cancer 
cells differ from that on normal cells.36,46 The abnormal glycosylations include loss or 
overexpression of certain glycans, presence of truncated glycans, and insertion of new 
glycans.47,48 A variety of abnormal glycans on tumor cells have been identified by 
immunohistochemical staining with lectin or monoclonal antibody (mAb) or by MS 
analysis.49,50 Abnormal glycans expressed on cancer cells are termed tumor-associated 
carbohydrate antigens (TACAs),72,92-95 some of which are depicted in Figure 1.2.  
TACAs are widely detected in the majority of common human cancers, including 
lung, breast, colorectal, ovarian, prostate, and pancreatic cancers. TACAs have been 
correlated to specific types of cancers, and each type of malignant tissue is often 
characterized by a distinct set of TACA expression as shown in Table 1.2.49,50 TACAs are 
thus employed as important biomakers for clinical diagnosis of cancer. On the other hand, 
TACAs are also attractive targets for anti-cancer vaccine and immunotherapy 
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development because they are usually abundantly expressed by many tumors but rarely 
or not expressed on normal cell surface.30,31  
 
Figure 1.2 Examples of TACAs 
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Table 1.2 Expression profiles of TACAs on malignant tissues49,50 
Tumor 
Tumor-associated carbohydrate antigens 
   
sLex Lex sLea Lea sTn Tn TF Ley Globo H PSA CD2 CD3 FucosylGM1 GM2 
B cell lymphoma           ✓   ✓ 
Breast   ✓  ✓ ✓ ✓ ✓ ✓     ✓ 
Colon   ✓  ✓  ✓ ✓      ✓ 
Lung ✓    ✓   ✓ ✓     ✓ 
Melanoma           ✓ ✓  ✓ 
Neuroblastoma          ✓ ✓ ✓  ✓ 
Ovary     ✓  ✓ ✓ ✓     ✓ 
Prostate     ✓ ✓ ✓ ✓      ✓ 
Sarcoma           ✓ ✓  ✓ 
Small cell lung   ✓      ✓ ✓   ✓ ✓ 
Stomach  ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓     ✓ 
 
1.3.2 TACA-based cancer vaccines  
TACA-based cancer vaccines have been widely explored despite of the potential 
problems associated with TACAs as described previously. In general, the production of 
immunity or antibodies induced by antigens depends on the cooperative function of two 
types of lymphocytes, B cells and helper T cells. However, the carbohydrate antigens are 
T cell-independent antigens and can hardly stimulate helper T lymphocytes. As a result, 
they only elicit B cell immunity which lacks long-term immunological memory and induce 
IgM antibodies that have low relatively affinity to antigens. On the other hand, the 
involvement of helper T cells in the immune reactions (T cell immunity) and the induction 
9 
 
of IgG antibodies, which correlate to long-term immunological memory, higher antibody 
affinity and improved antibody-dependent cell-mediated cytotoxicity,31,44,48,52 are 
important for effective cancer therapy. 
To formulate effective therapeutic cancer vaccines, the common strategy is to 
covalently link TACAs to a carrier protein to form conjugate vaccines that can induce T 
cell immunity. Keyhole limpet hemocyanin (KLH) is one of the most widely used carrier 
proteins for the design and development of glycoconjugate cancer vaccines because of 
its outstanding immunostimulatory ability.  By coupling TACAs to proteins, the immune 
responses to TACAs can switch from T cell-independent to T cell-dependent and lead to 
the production of IgG antibodies with higher affinity.22,27 The approach has been widely 
and successfully utilized to develop a number of TACAs-based vaccines. Some of these 
vaccines, such as Globo H-KLH and sTn-KLH conjugates as well as others, have been 
tested in clinical trials.53,54 Some of the vaccines studied and the carrier proteins used are 
listed in Table 1.3. 
Table 1.3 Examples of carbohydrate-based anticancer vaccines 
Target antigen Spacer/other epitope Carrier Cancer type 
Monomeric vaccine 
Globo H CH2CH2  KLH, 
BSA 
Breast55 
 MMCCH KLH Prostate, breast56,57 
Fuc-GM1 Ceramide-reductive amination KLH Small-cell lung58 
GD2 Ceramide-lactone KLH melanoma59 
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GD3 Ceramide-reductive amination KLH Melanoma60,61 
GM2 Ceramide-reductive amination KLH Melanoma62,63 
GM3 Proteoliposome OMPC Melanoma64 
Ley  CH2CH2 KLH Ovarian39 
sTn Crotyl linker KLH Breast, covarian and 
colorectal65-68 
PSA, NP-PSA Reductive amination KLH Small-cell lung69 
Tn MBS KLH, 
PAM 
Prostate70 
TF MBS KLH Prostate71 
sTn sTn(c)  crotyl linker-MMCCH KLH Breast72 
Gb3-MUC5Ac Gb2-norleucine-MUC5Ac-MBS KLH Ovarian73 
GM3NPhAc Immunotherapy based on 
glycoengineering  
KLH Melanoma74,75 
sTnNPhAc Immunotherapy based on 
glycoengineering 
KLH Epithelial cells related 
cancer76,77 
Polyvalent vaccine (pooled monomeric vaccines) 
GD3, Ley, MUC1 and 
MUC2 
(GD2)-reductive amination 
(Ley)-CH2 CH2 
(MUC1, MUC2)-MBS 
KLH Melanoma 
Ovarian 
Breast78 
GM2, Globo H, Ley, Tn 
and TF MUC1 (32mer) 
(GM2)-reductive amination 
(Ley, Globo H)-MMCCH 
(MUC1, Tn, TF)-MBS 
KLH Prostate79 
GM2, Globo H, Ley, Tn, 
TF, sTn and MUC1 
(GM2)-reductive amination 
(Ley, Globo H)-MMCCH 
KLH Epithelial ovarian, 
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(MUC1, Tn, TF, sTn)-MBS Fallopian tube or 
peritoneal80 
Unimolecular polyvalent vaccine (consists of multi-antigens on unimolecule) 
Globo H, Tn, sTn, TF, 
Ley and GM2 
Diaminopropyl-MBS KLH Breast and prostate81-
83 
Globo H, GM2, Tn, sTn 
and TF 
Diaminopropyl-MUC1-alanine-MBS KLH Breast84 
Multicomponent vaccine 
Fucosyl GM1 FucGM1-norleucine-MHC II binding 
peptide-MBS 
KLH Small-cell lung85 
Tn (Two components) Pam3Cys-aminobutyl-di-Tn86   
Ley (two components) Pam3Cys-peptide-(Ley)3  Ovarian87 
Tn, TF or STF Pam3CysSK4-ethylene glycol-MUC1  Breast88 
Tn and TF (three-
component branched) 
Pan-DR epitope-Lys-MUC1-Tn-Ala-
MUC1-TF 
 Breast89 
Tn (three component) TLR-2 ligand –Th epitope-MUC1-Tn  Breast42,43 
Tn (four component) TLR-2 ligand –CD8+ epitope 
(OVA257-264)-CD4+ epitope (Pan-
DR)- Tn 
RAFT Breast90,91 
sTnNPhAc sTnNPhAc-linker-MPLA; 
immunotherapy based on 
glycoengineering  
 Epithelial cells related 
cancer92,93 
GM3NPhAc GM3NPhAc-linker-MPLA; 
immunotherapy based on 
glycoengineering 
 Melanoma45 
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(c): cluster; Ala: alanine; BSA: Bovine serum albumin; CRM: Diphtheria toxin mutant; Fuc: Fucosyl; Gb3: 
Globosyltriaoside; GD: Ganglioside antige; Globo H: Globohexaosylceramide; GM: Gangliosidoses; KLH: 
keyhole limpet hemocyanin; Ley: Lewisy antigen; MBS: M-maleimidobenzoyl-N-hydroxysuccinamine ester; 
MMCCH: 4-(4-N-maleimidomethyl) cyclohexane-1-carbonylhydrazide; MUC: Mucin; MUC5Ac: Mucin 5, 
subtypes A and C; NP: N-propionylated; NPhAc: N-phenyl acetyl; OMPC: Neisseria meningitidis serogroup 
B outer membrane protein complex; OVA: Ovalbumin; PAM: Palmitic acid; Pam3Cys: Tripalmitoyl-S-
glyceryl-cysteinylserine; Pan-DR: CD4+ T-helper epitope peptide; PSA: polysialic acid; RAFT: 
Regioselectively addressable functionalized template; SK4: Serine-lysine-lysine-lysine-lysine; STF: sialic 
Thomsen-Friedenreich; sTn: Sialyl 2-6-α-N-acetylgalactosamine; TF: Thomsen-Friedenreich; Th: T helper; 
Tn: 2-6-α-N-acetylgalactosamine; TT: Tetanus toxoid.  
 
As tumor cells have multiple TACAs expressed on their surface, and in different 
stages of development, they have different kinds of TACAs. Therefore, polyvalent cancer 
vaccines containing multiple antigens is desirable for targeting transformed tumor cells. 
These polyvalent vaccines can be achieved by using a mixture of several monomeric 
vaccines individually containing one antigen78-80 or a unimolecular polyvalent vaccine 
consisting multi-antigens81-83 (Table 1.3). The pooled polyvalent vaccine of GD3-KLH, Ley-
KLH, MUC1-KLH and MUC2-KLH with QS021 adjuvant was found to elicit strong antigen-
specific IgG and IgM antibodies.78 Another vaccine pooled from GM2-KLH, Globo H-KLH, 
Ley-KLH, TF-KLH, Tn-KLH, sTn-KLH and MUC1-KLH had similar results.80 However, this 
mixture vaccine required more amount of carrier proteins and pre-validated vaccine 
component. To promote the polyvalent vaccine, the unimolecular vaccines consisting 
multi-antigens were developed. The KLH conjugates with Globo H, Tn, sTn, TF, Ley and 
GM2 was demonstrated to generate antigen-specific IgM and IgG antibodies which was 
similar as the other unimolecular polyvalent vaccines.81-83  
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Although these semi-synthetic vaccines have potential to be further used in clinic, 
they have some limitations. The reproducibility of protein conjugates is not consistent from 
batch-to-batch which induces the difficulty in safety control and quality control.9,42,43,94 To 
further overcome these problems, some new construct of vaccines with fully-synthetic 
chemical structures are in development. The examples of full-synthetic carbohydrate 
vaccine having robust immunogenicity without the use of a protein carrier or adjuvant 
were composed of TACAs and an immunologically active lipopeptide, tripalmitoyl-s-
glyceryl-cysteinylserine (Pam3Cyc).42,43,94 Our group developed novel full-synthetic anti-
cancer vaccine using monophosphoryl lipid A (MPLA) as a immunostimulatory carrier and 
build-in adjuvant and the animal studies demonstrated these vaccines induced excellent 
immune response, especially T cell immune response.45,92  
Another strategy for new construct of vaccines was developed by Huang’s group 
that they used tobacco mosaic virus and bacteriophage Qbeta virus-like particles as 
carrier to stimulate immune response.95,96 The key advantage of virus-like particles carrier 
is the ability to present antigens in an organized and high density manner. The antigen-
specific antibodies generated by these vaccines included IgG isotypes which reacted 
strongly with the native Tn antigens on human leukemia cells.95,96  
 
1.3.3 A novel cancer immunotherapeutic strategy 
Although promising, most vaccines made of natural TACAs failed in clinical trials, 
because of the lack of sufficient capability to generate effective immune responses.31 This 
problem is mainly caused by the immunotolerence of TACAs resulting from the similar 
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structure to self-antigens that induces the absence of immunological supervision.31,36,37 
Therefore, an approach to break immunotolerance to TACAs is employing unnatural 
TACA analogs instead of natural TACAs to induce strong immune response, especially T 
cell-mediated immunity which is required for successful cancer therapy. This hypothesis 
was proved by some earlier studies that unnatural TACA analogs really provoked strong 
immune response including both IgM and IgG antibodies.97,98 However, the antibodies 
elicited by the unnatural TACA analogs may have limited cross-reactivity to the natural 
TACAs on cancer cells which compromised the efficacy of immunotherapy. To overcome 
this problem, a novel immunotherapy strategy based on artificial TACA vaccine and cell 
glycoengineering was developed in our group.31,74,75,93 This novel strategy comprised of 
two steps. First, a vaccine with artificial glycan resident, such as artificial sialic acid 
residues, will be used to stimulate the immune response including a strong T cell immunity. 
Immediately after immune response being elicited, a precursor (mannosamine 
corresponding to sialic acids) with the same artificial modification will be employed to 
glycoengineer the target cells and enforce the cells specifically expressing the 
corresponding glycan antigens on cell surface.74 Subsequently, the pre-stimulated 
antibodies can recognized the target cells and kill them with the help of other stimulated 
components in immune system. (Figure 1.3) To carry out this novel immunotherapy 
strategy, our group have demonstrated that an array of cancer cells were efficiently 
engineered to express unnatural GM3 and sTn analogs, that is N-phenylacetyl GM3 
(GM3NPhAc) and sTn (sTnNPhAc) by the treatment of precursor, N-phenylacetyl-D-
mannosamine (ManNPhAc). The previous studies also revealed that vaccines based on 
GM3NPhAc and sTnNPhAc can provoked strong T cell-mediated immune responses 
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which exhibited strong and specific complements-dependent cytotoxicity (CDC) to the 
pre-glycoengineered melanoma cell lines.31,45,74-77,93 This strategy was verified as a novel 
and selective cancer immunotherapy although the selectivity of this strategy for tumor in 
vivo need to be further investigated.31  
 
 
Figure 1.3 A novel immunotherapy strategy based on glycoengineering 
 
1.4 Carbohydrate-Based Antibacterial Vaccines 
The polysaccharides (PS), either a capsule or lipopolysaccharide, uniquely 
expressed on the surface of bacterial pathogens are attractive targets for anti-bacterial 
vaccine designs and immunotherapies.1 Recently, since the antibiotic-resistant problems 
in traditional clinical treatment of bacterial pathogens, the development of capsular 
polysaccharides-based vaccines have engendered increasing excitement.20,99-101 For 
many bacterial infections, some vaccines have been made from the fragment of bacterial 
capsular polysaccharide, such as Haemophilus influenza type b (Hib), Neisseria 
meningitides A, C, Y and W-135, and Salmonella typhi, and have been approved for 
clinical using.1 (Table 1.4)  
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Table 1.4 Examples of licensed carbohydrate-based vaccines1 
Target pathogen Vaccine Manufacture (Trade name) 
Haemophilus influenzae 
type b (Hib)  
Glycoconjugate, polysaccharide with 
tetanus toxoid (TT) 
Sanofi Pasteur (ActHIB,1993); 
GlaxoSmithKline Biologicals 
(Hiberix, 1998, EU) 
Diphtheria toxoid (DT), TT and acellular 
pertussis adsorbed, inactivated poliovirus 
and Hib-TT conjugate vaccine 
Sanofi Pasteur (Pentacel) 
Hib conjugate (meningococcal protein 
conjugate) 
Merck & Co (PedvaxHIB, 1990) 
Hib conjugate (meningococcal protein 
conjugate) and hepatitis B (recombinant) 
vaccine 
Merck & Co (Comvax) 
Synthetic oligosaccharides with TT 
conjugate 
Licensed in Cuba (Quimihib 
2004)33 
Neisseria meningitides 
A, C, Y and W-135 102 
Glycoconjugate, meningococcal 
polysaccharide with DT 
Sanofi Pasteur (Menactra, 
2005) 
Meningococcal polysaccharide without 
carrier 
GlaxoSmithKline (ACWY Vax, 
1981) 
Meningitidis A, C, Y and W-135 
polysaccharide with CRM197 
Novartis (Menveo, 2010) 
Salmonella typhi Vi capsular polysaccharide Sanofi Pasteur (Typhim Vi, ) 
Streptococcus 
pneumoniae 
Capsular polysaccharide with CRM197 Wyeth (Prevnar 13, 2000) 
Capsular polysaccharide Merck & Co (Pneumovax 23, 
1983) 
(From the US Food and Drug Administration website and www.cdc.gov/vaccine ) 
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However, the heterogeneity and complexity of capsular polysaccharides cause the 
difficulties and complicacy in the development of efficient carbohydrate-specific 
vaccines.39-42 Moreover, using naturally derived polysaccharides to produce protein 
conjugate vaccines presents the challenges in quality control and safety standards as 
described above. Therefore, to overcome these problems, synthetic glycans with well-
characterized carrier proteins or full-synthetic vaccines with a well-defined synthetic 
carrier can be the future directions.33,103  
The first approved full-synthetic glycan-based vaccine, Quimi-Hib, was developed 
in Cuba to prevent from Hib infection.33 The synthetic ribosylribitol-phosphate (RRP) 
repeat units have been proven efficient in provoking immunity and can be accessed by 
large-scale good manufacturing practice production. This promising production strategy 
of vaccine incorporating a synthetic bacterial carbohydrate antigen reduced the safety 
problems which existed in the purification of saccharide fragments from bacteria culture 
and provided effective vaccine as already-licensed vaccine for human use. This strategy 
was therefore feasible and can be further applied in the development of vaccines against 
other pathogens.33 However, the reassembling Hib polysaccharide fragments were the 
mixture of several RRP repeat units but not single structure.  
To further study the structure-immunogenicity relationships of saccharide moieties 
in a conjugate vaccine and optimize a well-defined glycoconjugate vaccine, in our group, 
two series of oligosaccharide fragments, mimicking the antigens from Hib or N. 
meningitidis, respectively, were synthesized and were conjugated with KLH or MPLA 
carriers individually. The chapter 4 of this dissertation will focus on the immunological 
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studies of these semi-synthetic and full-synthetic anti-bacterial vaccines in animal, and 
the investigation of structure-immunogenicity relationships. (Figure 1.4)  
 
Figure 1.4 Anti-bacterial vaccines based on capsular polysaccharides 
 
1.5 Conclusion 
Carbohydrate antigens are attractive targets for immunotherapy and vaccine 
development against bacteria, fungi, virus and cancers. However, there are a lot of 
problems existing in the development of efficient vaccines. To overcome these problems, 
many approaches have been explored. In our lab, a novel immunotherapy strategy based 
on glycoengineering was developed to overcome the immunotolerance of TACAs. 
Another novel construct of vaccine based on monophosphoryl lipid A (MPLA) was 
explored. The achievements based on these two pioneering ideas will be exhibited in this 
dissertation including the investigation of glycoengineering efficiency, a series of anti-
cancer vaccines based on TACAs with MPLA as carrier, and two series of anti-bacterial 
vaccines.  
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CHAPTER 2 Quantifying the Efficiency of Sialic Acids Metabolic Engineering 
 
2.1 Introduction of Sialic Acid Metabolic Engineering 
Sialic acids are a family of nine-carbon keto carbohydrates, and the most common 
member is N-acetyl neuraminic acid (Neu5Ac, Figure 2.1). Neu5Ac is usually present at 
the non-reducing end of glycans and plays important roles in various biological processes, 
such as specific recognition, binding and regulatory events.1,2 It is also well known that 
Neu5Ac is typically overexpressed on the surface of cancer cells3 and many of the 
uniquely or excessively expressed glycans on cancer cells, known as tumor-associated 
carbohydrate antigens (TACAs),4 contain the Neu5Ac residue. Some sialo-TACAs, such 
as α-2,8-polysialic acid, sTn antigen, sialy Lewis antigens and the GM and GD 
gangliosides, are abundantly expressed by a number of tumors. Therefore, sialo-TACAs 
are useful targets for the design and development of new strategies for cancer diagnosis 
and immunotherapy.5-7 However, most native TACAs are poorly immunogenic and 
tolerated by the patients’ immune system; therefore, they may not be able to induce robust 
antitumor immune responses, especially T cell-dependent immune responses, in cancer 
patients. 
 
 
Figure 2.1. Structure of Neu5Ac 
To deal with the immunotolerance problem of TACAs, we have explored a novel 
strategy for cancer immunotherapy based on metabolic engineering of cancer cell surface 
sialo-TACAs.8,9 A key step of this strategy is to give cancer cells an unnatural analog of 
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N-acetyl-D-mannosamine (ManNAc), the native biosynthetic precursor of Neu5Ac, to 
bioengineer cancer cells to express an unnatural sialo-TACA analog10,11 (Figure 2.2) that 
is more distinguishable and immunogenic than the natural TACA to enable effective cancer 
immunotherapy.8 Using antigen-specific antibodies combined with bioassays such as 
ELISA and flow cytometry,12,13 we have demonstrated that N-phenylacetyl-D-
mannosamine (ManNPhAc) could metabolically engineer cancer cells to express sialo-
TACA analogs, such as analogs of sTn and GM3, carrying unnatural N-phenylacetylsialic 
acid (Neu5PhAc) residues. However, these were only qualitative and semiquantitative 
analyses. To ultimately determine the efficiency of ManNPhAc to metabolically engineer 
cancer cells, a reliable method to quantify the ratio of Neu5Ac and Neu5PhAc expressed 
by cancer cells is required, which is the aim of this research. 
 
 
Figure 2.2 Metabolic engineering of sialic acids on the cancer surface 
 
2.2 Results and Discussion 
In the literature several methods have been described for the analysis of sialic 
acids, such as colorimetric and fluorometric assays after derivatization with thiobarbituric 
acid14,15 and liquid chromatography (LC) with UV,16 fluorescence17-27 and mass 
spectrometry (MS) 28-32 detection. Except for LC-MS, sialic acids must be derivatized to 
be photometrically detectable. In addition to thiobarbituric acid,14,15 a number of reagents 
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including 3,4-diaminotolenene,32 1,2-diamino-4,5-dimethoxybenzene,17 O-
phenylenediamine,20 and 1,2-diamino-4,5-methylenedioxybenzene (DMB),21,22,24-29,33-35 
have been used for sialic acid derivatization, taking advantage of the special α-keto acid 
functionality. Among these methods, DMB derivatization for HPLC-fluorescence and LC-
MS analyses was the most popular due to the high sensitivity and selectivity of the 
reaction involved. In this research, we aimed at a potentially broadly applicable method 
that uses simple instrument. Therefore, we became interested in a method that was 
based on HPLC separation and UV detection. To make sialic acids UV-detectable, we 
planned to employ DMB for sialic acids derivatization.29,35,36 As shown in Figure 2.3, the 
resulting DMB derivatives had strong maximum absorbance at 370 nm, which was utilized 
for quantitative analysis. Consequently, our design for the sialic acid analysis was to 
release the total sialic acids from cell surfaces under mild acidic conditions, derivatize 
them with DMB and finally subject the mixture to HPLC analysis with UV detection at 370 
nm.  
 
 
Figure 2.3 Reactions between sialic acids and DMB and structures of the reaction 
products 
 
To verify that DMB derivatization of sialic acids can be used for quantitative 
analysis and that the HPLC signals of corresponding sialic acid derivatives have a linear 
relationship with the concentrations of Neu5NAc and Neu5PhAc and to establish proper 
calibration curves, different concentrations of standard Neu5NAc and Neu5PhAc samples 
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were treated with DMB and then applied to HPLC-UV analysis. It was revealed that the 
reaction was clean and complete and the HPLC retention times (C18 column, 0.5 μm, 
250 × 4.6 mm; eluted with water and acetonitrile containing 0.1% trifluoroacetic acid (TFA): 
acetonitrile concentration changed from 5% to 25% in 10 min, kept at 25% for 10 min, 
then from 25% to 70% in 15 min; flow rate: 1mL/min) for the Neu5Ac and Neu5PhAc 
derivatives 2.3 and 2.4, which were confirmed with MS, were 9.87 min and 15.45 min, 
respectively. As shown in Figure 2.4, under the tested conditions (i.e., Neu5Ac and 
Neu5PhAc concentrations in the range of 15-130 µM), the observed HPLC peak areas of 
2.3 and 2.4 were in good linear relationship (coefficient: 0.9814 and 0.9763, respectively) 
with the Neu5Ac and Neu5PhAc concentrations in the samples. These results have 
demonstrated that the method could be used for the quantification of Neu5Ac and 
Neu5PhAc. Equations, HPLC peak area = 2067 [Neu5Ac] + 18,835 and HPLC peak area 
= 1832 [Neu5PhAc] – 1,141, were used to calculate the concentrations or quantities of 
Neu5Ac and Neu5PhAc in samples, respectively.  
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Figure 2.4 A linear correlation between the peak areas of Neu5Ac or Neu5PhAc 
derivative and the concentrations of Neu5Ac or Neu5PhAc was demonstrated.  The 
coefficient of determination (R2) is displayed for each graph. 
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For the analysis of biological samples derived from cells, there are several issues 
that may be of concern. First, the detachment of sialic acids from the cell surface may not 
be complete, which can affect the observed amount of sialic acids. However, this is a 
systematic error that may affect the sample recovery but not the ratio of Neu5Ac and 
Neu5PhAc, the latter of which is actually our focus. Second, the collected sialic acids 
need to be derivatized before analysis, while under the condition that the samples contain 
numerous impurities, whether the derivatization reaction will be affected is another 
question, despite that the above experiments have proved the reaction efficiency in the 
absence of impurities. Third, samples derived from metabolically engineered cells will 
contain variable ratios of Neu5Ac and Neu5PhAc, which can be immensely different. 
Whether this can be accurately reflected is another question.  
To address these issues, we then probed the reliability and accuracy of the 
proposed method under more complex situations, such as for the analysis of biologic 
samples or samples with big differences in the Neu5Ac and Neu5PhAc concentrations. 
To probe the reliability of the method, we added different amounts of Neu5PhAc in the 
culture of SKMEL-28, a melanoma cell line, and then examined its recovery upon a series 
of treatments involved in the real sample analysis, including incubation with acetic acid 
employed to detach sialic acids from cells, lyophilization, reaction with DMB, and 
eventually HPLC analysis. As shown in Table 2.1, the recovery rates of the externally 
added Neu5PhAc in various samples were excellent (97-99%, average 98±1%). In this 
study, the recovery of Neu5Ac from cells was not examined, as the added Neu5Ac would 
interfere with naturally exiting Neu5Ac. However, we anticipated that its recovery rate 
should not be lower than that of Neu5PhAc. To probe the accuracy of the method, we 
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prepared a series of Neu5Ac and Neu5PhAc mixtures in ratios ranging from 100:0 to 
100:8 and applied them to analysis by the proposed method. As shown in Table 2.2, the 
experimental results were in good agreement with the expected ratios, and in average 
the accuracy was above 93%. These results have clearly demonstrated the reliability and 
accuracy of the proposed method for the analysis of Neu5Ac and Neu5PhAc expressed 
by metabolically engineered cells. 
 
Table 2.1 Recovery analysis of Neu5PhAc from the SKMEL-28 cell culture 
Added Neu5PhAc (nmol) 65 130 130 130 
Detected Neu5PhAc (nmol) 63 128 127 129 
Recovery rate (%) 97 98 98 99 
 
Table 2.2 Analysis of Neu5Ac and Neu5PhAc mixtures prepared in different ratios 
Sample number 1 2 3 4 5 
Standard samples 
Neu5Ac:Neu5PhAc 
100:0 100:2 100:4 100:6 100:8 
Experimental results 
Neu5Ac:Neu5PhAc 
100:0 100:1.9(±0.1) 100:3.7(±0.1) 100:5.9(±0.3) 100:7.1(±0.4) 
 
After the proposed method was verified with standard samples under different 
conditions, it was applied to the analysis of metabolically engineered cancer cells. In 
these studies, SKMEL-28 cells were incubated with various concentrations of ManNPhAc 
(0, 5, 10, 20, and 30 mM) for 2-4 days. Then, ca. 1.0 × 106 cells were harvested from 
each culture, washed, and treated with 2 M acetic acid at 80 ºC for 2 h to release sialic 
acids from cells. This was followed by lyophilization and reaction with excessive DMB at 
50 ºC for 3 h.29 After the reaction mixtures were filtered off through a 0.22 μm film, they 
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were subjected to analysis by RP-HPLC using gradient eluents of water and acetonitrile 
containing 0.1% TFA. Figure 2.5 shows the typical HPLC diagram of a sample. As labeled 
in the figure, the DMB derivatives of Neu5Ac and Neu5PhAc 2.3 and 2.4 had the same 
retention times as that of the standard samples. To further prove their identity, 2.3 and 
2.4 were collected and subjected to MALDI-MS analysis, which gave the correct masses 
[m/z: calculated, 425.2 and 501.2; observed, 426.3 and 502.5 (M+H+), respectively]. 
Evidently, the samples also contained a small number and amount of other impurities, 
which appeared at different positions and did not affect the analysis.  
 
 
Figure 2.5 HPLC diagram of a sample derived from 106 SKMEL-28 cells treated with 30 
mM of ManNPhAc for 3 days. The retention times for the DMB derivatives of Neu5Ac and 
Neu5PhAc 2.3 and 2.4 were about 9.90 and 15.50 min, respectively. 
 
The amounts of Neu5Ac and Neu5PhAc in samples obtained from 106 SKMEL-28 
cells were calculated based on the HPLC peaks of 2.3 and 2.4 according to the standard 
curves shown in Figure 2.4, and the results are presented in Figure 2.6. As anticipated, 
significant Neu5PhAc expression was observed for cells incubated with 5 mM of 
0
50000
100000
150000
200000
250000
0 5 10 15 20
Retention Time (min)
P
ea
k 
In
te
n
si
ty
3
4
35 
 
ManNPhAc (Figure 2.6B), and the amount of expressed Neu5PhAc increased 
proportionally with the increase of ManNPhAc concentration in the cell culture. However, 
Neu5PhAc expression was still much lower than that of Neu5Ac even at a quite high 
concentration (30 mM) of ManNPhAc. Furthermore, it was found that natural Neu5Ac 
expression was also elevated in the presence of high concentrations of ManNPhAc. 
Typically, one should expect that natural product biosynthesis would be depressed on the 
addition of an unnatural biosynthetic precursor due to either competition or inhibition. In 
contrast, it was very interesting to notice that the presence of ManNPhAc seemed to 
promote not only Neu5PhAc expression but also Neu5Ac biosynthesis, which is unique 
and can be of biological significance, so it is worthy further investigation. Conclusively, 
the results suggested that ManNPhAc could effectively glycoengineer SKMEL-28 cells to 
express unnatural Neu5PhAc in a concentration-dependent manner in the range of 5-30 
mM, whereas Neu5Ac expression was only slightly affected under the same condition. It 
was also evident that only a small fraction of Neu5Ac on the cell surface was substituted 
with Neu5PhAc upon metabolic engineering using ManNPhAc, a process that had to 
compete with the endogenous biosynthetic pathway.  
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Figure 2.6 The amounts of Neu5Ac (A) and Neu5PhAc (B) expressed by SKMEL-28 cells 
(106) that were incubated with 0, 5, 10, 20 and 30 mM of ManNPhAc for 3 days, 
determined by HPLC. Error bar represents the standard deviation of three parallel 
experiments. 
 
To further define the efficiency of cell metabolic engineering using ManNPhAc, the 
percentage of Neu5PhAc expressed on the cell surface in terms of total sialic acids was 
calculated according to the following equation, Neu5PhAc% = Neu5PhAc /(Neu5Ac + 
Neu5PhAc) x 100%, and the results are shown in Figure 2.7(A). The percentage was 
about 2.2% and 5.8% for cells incubated with 5 mM and 30 mM of ManNPhAc for 3 days, 
respectively.   
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Figure 2.7 The percentages of Neu5PhAc expressed on SKMEL-28 cells incubated with 
0, 5, 10, 20 and 30 mM of ManNPhAc for 3 days (A), and the percentages of Neu5PhAc 
on SKMEL-28 cells incubated with 5 and 20 mM of ManNPhAc for 2, 3, 4 and 9 days (B), 
respectively. The error bar represents the standard deviation of three parallel experiments. 
 
Finally, we examined the influence of incubation time on the cell engineering 
efficiency. In these studies, we incubated cancer cells with 5 mM and 20 mM of 
ManNPhAc for 2, 3, 4 and 9 days, and then examined their Neu5PhAc expression. The 
results (Figure 2.7B) indicated that the percentage of Neu5PhAc increased during the 
first 3 days to reach peak values at day 3 and then decreased slightly to retain a consistent 
level of Neu5PhAc after day 4. The reason for decreased Neu5PhAc expression after day 
3 was not clear, but it might be due to the change of metabolic activities of the cell, as we 
found that after 3 days of incubation cell proliferation and growth became slower. 
Nevertheless, it was ultimately disclosed that cancer cells could be effectively engineered 
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to express a significant level of unnatural Neu5PhAc to make the cells distinct and that 
this could persist for a long period. 
2.3 Conclusion 
We have developed a convenient and reliable method for quantitative analysis of 
sialic acids expressed by cells. This method was based on the specific reaction between 
DMB and the α-keto acid functionality of sialic acids to generate products that had strong 
UV absorption, enabling easy HPLC analysis with UV detection. After the consistency 
and accuracy of this method were verified with standard samples under various conditions, 
it was used to analyze metabolically engineered cancer cells, which expressed both 
natural Neu5Ac and unnatural Neu5PhAc.  
The protocols for this analysis were rather straightforward. After incubation with 
ManNPhAc, cells were subjected to acetic acid-promoted hydrolysis to release sialic 
acids on the cell surface. Then, the sample was lyophilized and treated with DMB. The 
reaction mixture was directly applied to HPLC analysis to determine the amounts and 
ratio of Neu5Ac and Neu5PhAc. The method is not only applicable to the analysis of 
Neu5Ac and Neu5PhAc but also generally useful for the analysis of other sialic acids.  
While this is a simple, reliable and quantitative method, it does have limitations. 
For example, it is not easily applicable to the analysis of cells incubated with µM 
concentration of ManNPhAc, probably because the Neu5PhAc expression level was too 
low. However, Neu5PhAc expression on these cells was detected by flow cytometry with 
the help of antibody-labeling.13 Evidently, flow cytometry is more sensitive, albeit not 
precisely quantitative, than HPLC analysis. Another problem for the flow cytometry 
method is that it relies on antigen-specific antibodies that are not always readily available. 
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Therefore, a combination of these two analytical methods can portrait the whole picture 
concerning the metabolic engineering of cell surface sialic acids with unnatural ManNAc 
derivatives as biosynthetic precursors.  
This research has revealed for the first time that more than 2% of Neu5Ac was 
substituted for Neu5PhAc upon metabolic engineering with ManPhNAc. We have 
previously shown by means of flow cytometry13 and antibody-mediated cytotoxicity37 that 
cancer cells could be engineered to express Neu5PhAc at low µM concentrations (20-50 
µM) of ManNPhAc. Under these conditions, the expression level of Neu5PhAc should be 
much lower than 2%, but the engineered cells could be recognized by Neu5PhAc-specific 
antibodies and undergo functional immune reactions. This information is useful not only 
for our immunotherapy but also for other studies that are based on metabolic engineering 
of cell surface sialic acids or other sugars. A particularly interesting but unexpected 
discovery was that natural sialic acid expression also increased in the presence of 
ManNPhAc, which could be only disclosed from quantitative analysis. This may be of 
biological significance, as sialic acid expression is related to various biological activities, 
and it is worthy further investigation.  
 
2.4 Experimental Section 
Materials, reagents and animals 
SKMEL-28 cell line, Dulbecco’s Modified Eagle’s Medium (DMEM) for cell culture, 
and fetal bovine serum (FBS) were purchased from American Type Culture Collection 
(ATCC). Penicillin-streptomycin and trypsin-EDTA were purchased from Invitrogen. 
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ManNPhAc was synthesized by a procedure previously reported by our laboratory.13 DMB, 
sodium hydrosulfite, β-mercaptoethnal and other chemicals were purchased from Sigma.  
Metabolic engineering of tumor cell 
SKMEL-28 cells were cultured in DMEM containing 10% of FBS, 1% of penicillin-
streptomycin and various concentrations (0 to 30 mM) of ManNPhAc at 37 oC. After a 
certain number of days of incubation, cells were harvested upon treatment with trypsin-
EDTA solution, and finally washed twice with PBS to be readied for further analysis.  
Hydrolysis of sialic acids 
A cell sample (containing about 1.0×106 cells) was dissolved in a 2 M solution of 
acetic acid (2 mL). The mixture was stirred at 80 ºC for 2 h, and then lyophilized to get a 
powder product that contained sialic acids released from cells.  
DMB derivatization of sialic acids and HPLC analysis 
The powder product obtained above was mixed with DMB (0.5 mg, excessive) in 
1.4 M acetic acid containing 18 mM of sodium hydrosulfite and 0.75 M of β-
mercaptoethnal.29 After the reaction mixture was stirred at 50 ºC for 3 h, it was filtered off 
through a 0.22 μm film, and the filtrate was analyzed by RP-HPLC (C18 column, 250 × 
4.6 mm, 0.5 μm) using gradient eluents of water (A) and acetonitrile (B) containing 0.1% 
TFA at flow rate of 1mL/min. Elution started with 5% B, which was increased gradually to 
25% B in 10 min. Elution of the column with 25% B was kept for 10 min, followed by 
gradual increase of B composition to 70% within 15 min, and the elution was kept under 
this condition to the end of an experiment. Finally, the column was washed and balanced 
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with 5% B for 40 min before the next experiment. The eluents were monitored with a UV 
detector at 370 nm, at which wavelength DMB derivatives of sialic acids had the maximum 
absorption. All of the HPLC peaks were separately collected, and the fractions containing 
the anticipated DMB derivatives of sialic acids were further analyzed and verified by 
MALDI-MS. 
Establishment of standard calibration curves and equations used to quantify 
Neu5Ac and Neu5PhAc 
A Neu5Ac or Neu5PhAc standard sample (1, 2, 4 or 6 µg) was mixed with a DMB 
reaction solution (150 µL containing 0.5 mg DMB, excessive) in 1.4 M acetic acid, 18 mM 
of sodium hydrosulfite and 0.75 M of β-mercaptoethnal. The reaction mixture was stirred 
at 50 °C for 3 h, and then filtered off through a 0.22 µm film. The filtrate (10 µL) was 
analyzed by RP-HPLC (C18 column, 250 × 4.6 mm, 0.5 µm) using gradient eluents of 
water and acetonitrile containing 0.1% TFA at flow rate of 1 mL/min as described above. 
The eluents were monitored with a UV detector at 370 nm. The peak areas were plotted 
against the sample concentration to obtain the calibration curves and equations. 
Determining the recovery rate of Neu5PhAc from cell culture 
SKMEL-28 cell was cultured, harvested, and washed twice with PBS. To the cell 
sample (about 1.0 × 106 cells, in 1 mL PBS solution) was added 65 or 130 nmol of a 
Neu5PhAc standard sample. The cell sample was added to an acetic acid solution (final 
volume 2 mL and final concentration 2 M). The mixture was stirred at 80 °C for 2 h. The 
reaction mixture was lyophilized to obtain a powder product that was reacted with a DMB 
solution (150 µL, containing 0.5 mg DMB) in 1.4 M acetic acid containing 18 mM of sodium 
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hydrosulfite and 0.75 M of β-mercaptoethnal. The reaction mixture was finally subjected 
to HPLC analysis as described above. 
Determining the Neu5Ac and Neu5PhAc ratios in standard samples 
A series of standard samples containing different ratios of Neu5Ac and Neu5PhAc 
(100:0, 100:2, 100:4, 100:6, 100:8 mol/mol) were prepared. About 20 nmol of each 
sample was added to a DMB solution (150 µL, containing 0.5 mg DMB) in 1.4 M acetic 
acid containing 18 mM of sodium hydrosulfite and 0.75 M of β-mercaptoethnal. After the 
reaction mixture was stirred at 50 °C for 3 h, it was filtered off through a 0.22 µm film, and 
10 µL of the filtrate was finally subjected to RP-HPLC analysis as described above.  
 
2.5 Appendices 
Mass Spectrum Confirmation 
The fraction of 15.45 min of HPLC was collected to be further confirmed by MALDI-
TOF MS (Figure 2.8). In the standard Neu5PhAc-DMB mass spectrum, the MALDI peaks, 
501.800 (M+H+) and 523.676 (M+Na+) confirmed that the standard Neu5PhAc was 
successfully labeled with DMB. In the HPLC fraction of 15.4 min collected from cell 
samples treated with precursor, the peaks, 502.536 (M+H+) and 524.258 (M+Na+), 
confirmed that the cells expressed the modified sialic acid as expected . The mass error 
was due to the system shift of m/z value in MALDI machine.  
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Figure 2.8 MALDI MS of Neu5PhAc-DMB: (A) Sample was from reaction solution of 
standard Neu5PhAc after DMB derivatization; (B) HPLC fraction sample of 15.4 min in 
the cell samples which was treated with 20 mM precursor ManNPhAc for 2 days. 
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CHAPTER 3 Development of Anti-Cancer Vaccines Using Monophosphoryl Lipid 
A as a Carrier Molecule and Built-in Adjuvant 
 
3.1 Introduction of Monophosphoryl lipid A (MPLA) 
3.1.1 Lipopolysaccharide  
The endotoxins were first found in heat-killed bacteria Vibrio cholera by Richard 
Pfeiffer and Robert Koch in the nineteenth century and were associated primarily with 
Gram-negative bacteria.1 They are distinguished from exotoxin because the former are 
not secreted to the culture media by bacteria but only released upon lysis of bacteria cells. 
The principal endotoxin, lipopolysacchride (LPS) which is a family of complex glycolipid, 
is the major component of the outer monolayer of Gram-negative bacteria cell outer 
membrane.2 LPS was discovered as a heat-stable and amphiphilic components 
containing a hydrophobic lipid A as a membrane anchor domain, an oligosaccharide ‘core’, 
and a distal polysaccharide (Figure 3.1).3  
 
Figure 3.1 The structure of outer layer of outer membrane of Gram-negative bacteria.  
48 
 
The LPS layer of the outer membrane plays important roles in bacteria activities, 
such as reacting to the changes of environment and inhibiting toxic compounds (e.g., 
antibiotics) to protect the bacteria cell, working for nutrient transport, and mediating 
interaction with the host.4 The outer membrane with LPS can associate with divalent 
cations to provide an effective permeability barrier for the bacteria cell against external 
stress factors.5-7 Moreover, LPS has been demonstrated to be an extremely powerful 
immunostimulators and elicit toxic effects by inhibiting cellular functions or killing host 
cells. According to present knowledge about LPS, it interacts with various types of host 
cells including mononuclear cells, endothelial cells, smooth muscle cells, 
polymorphonuclear granulocytes, thrombocytes and so on through its lipid A component. 
Consequently, LPS has engendered considerable interests for antibiotics development 
because of its important role in antibiotics resistant and for immunotherapy development 
because of its strong immunostimulatory ability.  
 
3.1.2 Lipid A structure-activity relationships 
In general, the lipid A domain of LPS determines its principal immunostimulatory 
ability because lipid A itself is a potent toxin that can be specifically and sensitively 
recognized by immune system.8 Lipid A binds specifically to the toll or interleukin-1 
receptor domain-containing adaptor-inducing interferon-β (TRIF) of toll-like receptors 
(TLRs) in association with MyD88 to induce a downstream signaling cascade, stimulate 
the release of cytokines and chemokines, such as tumor necrosis factor-α (TNF-α), 
interleukin-1β (IL-1β), IL-6 and interferon-β (IFN-β), and upgrade immune cell 
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expression.9 Although the immunostimulatory activity of lipid A can be extremely useful, 
its pro-inflammatory and septic properties are a serious problem.10  
Regardless of the source, all lipid As contain the highly conserved construct as 
illustrated in Figure 3.2. They have several lipids, varying considerably in chain length, 
saturation, number and distribution, linked to the N-2-, N-2’-, O-3- and O-3’- positions and 
two phosphate groups linked to the O-1 and O-4’- positions of the β-1,6-linked 
disaccharide of D-glucosamine (GlcNH2).  
 
Figure 3.2 An example of lipid A structure. 
Biological assays demonstrated that the number, structure and position of lipids 
and the degree of phosphorylation are important factors determining the bioactivity of lipid 
A.2,3 To learn the structure-activity relationships of lipid A, studies were performed using 
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a murine macrophage cell line and human peripheral monocytes. The mediator-inducing 
capacity of various lipid A derivatives carrying synthetic partial structures were 
quantitatively analyzed. The results are schematically summarized in Figure 3.3.2-4 
 
Figure 3.3 Schematic representation of lipid A structure-activity relationships. 
As showed in Figure 3.3, once one of the phosphoryl groups in lipid A was 
removed, the bioactivity was reduced significantly (by a factor of 102 as compared to 
parent lipid A). The resulting monophosphoryl lipid A (MPLA) derivatives still had strong 
immunostimulatory ability but much reduced toxicity, thus they can be very useful. The 
monosaccharide derivatives had the least activity (reduction of activity by a factor of more 
than 107). In addition, substituting the α-anomeric phosphate group with the β-anomer 
significantly reduced the bioactivity, and modifications in the hydrophobic region of lipid 
chains had dramatic effects as well.2-4  
The number of lipid chains also affected the bioactivity significantly.2-4,11 A typical 
lipid A that exhibits the full spectrum of immunological and endotoxic activities consists of 
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six lipids that can be distributed symmetrically (3+3), such as in the lipid A of Neisseria 
meningitides, or asymmetrically (4+2), such as in the lipid A of Escherichia coli, on the 
two GlcNH2 units. Abstraction of one acyl group (resulting in pentaacyl lipid A) or addition 
of a fatty acid (resulting in heptaacyl lipid A) reduced the bioactivity by a factor of 102. 
However, abstraction of two acyl groups (resulting in tetraacyl lipid A) caused complete 
loss of the mediator-inducing capacity (a factor of > 107). Therefore, tetraacyl lipid A was 
an antagonist for the signaling activation rather than an agonist. The hydroxide group in 
the lipid chains also affect the immunostimulatory activity of lipid A by about a factor of 
101.2,4  
To further investigate the action mechanisms and the structure-activity 
relationships of lipid A, its interaction with the toll-like receptor 4 (TLR4)-MD2 signaling 
pathway that is activated by LPS or lipid A binding was analyzed.12 Most lipid A molecules 
can be detected at picomolar levels by TLR4, a receptor of the innate immune system, 
present on macrophages and endothelial cells. TLR4 is a class 1 transmembrane 
receptor with an extracellular domain, a single membrane spanning helix and a globular 
cytoplasmic domain, the TIR (Toll interleukin-1 receptor) domain. Another important lipid-
binding protein is MD2 which can form a TLR4-MD2 heterodimer.13 Binding of LPS to 
TLR4-MD2 is mediated by the intercalation of the acyl chains of lipid A into the 
hydrophobic core of the MD2 β-sandwich pocket that is similar to that formed by the 
immunoglobulin domains of antibody molecules.11-19  
Generally, hexa-acyl lipid A is a TLR4 agonist, whereas tetra-acyl lipid A that has 
different binding conformation with MD2 is an antagonist.18,19 For the tetra-acyl lipid A, 
two of the acyl chains, but four for hexa-acyl lipid A, can fully extended into the binding 
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pocket of MD2, while two are bent in the center. The tetra-acyl lipid A-MD2 ligand does 
not induce a conformational change in the receptor, which makes it an antagonist. The 
rest of lipid A, including the diglucosamine backbones, is fully exposed.17 The MD2-LPS 
complex binds TLR4 to form a higher order structure, creating an activation cluster that 
stimulates the following MyD88-dependent signal pathway. This signal pathway finally 
leads to production of inflammatory cytokines such as IL-12, IL-1, IL-6 and TNFα.20 
In conclusion, LPS, especially its lipid A domain, has potent immunostimulatory 
ability that can be very useful for various immunological studies and immunotherapeutic 
applications.  However, it is worth mentioning that the structure-activity relationship 
studies of lipid A were performed in vitro instead of in vivo.  
3.1.3 Monophosphoryl lipid A 
From the structure-activity relationship investigations described above, it is clear 
that the two phosphate groups in lipid A are essential for its endotoxic activity. However, 
modification of its O-1-position, for example, removal of the phosphate group at this 
position to generate monophosphoryl lipid A (MPLA), was shown to greatly reduce its 
endotoxicity (at most only 0.08% of toxicity remains)21 with limited impact (by a factor of 
102)4 on its immunostimulatory activity. As a result, MPLA has emerged as a potential 
adjuvant used in human vaccine formulation.22 The clinical grade of MPLA, called MPL 
adjuvantTM manufactured by GlaxoSmithKline showed approximately 0.1% the toxicity of 
LPS in pre-clinical rabbit pyrogenicity assays.23 MPL adjuvant is usually added to an 
adjuvant system, such as alum and water-oil form adjuvant, instead of replacing the other 
adjuvant. For example, MPL adjuvant has been widely used in adjuvant systems, such 
as AS01, AS02, and AS04. AS04 is a licensed adjuvant system containing MPLA and 
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alum, which elicits a major immune reaction including antibodies and Th1 immune 
responses (Table 3.1).  
Table 3.1 Adjuvant types and their mechanisms of action 
Adjuvant 
type 
Examples Mechanisms of action 
Type A MPLA Agonists for TLRs, indirectly, activating APCs and triggering the 
secretion of cytokines22 
Type B Alum, MF59, liposomal 
adjuvants 
Non-specific adjuvant, enhancing antigen presentation by building 
a depot at the injection site, leading to a high local antigen 
concentration and improving uptake by APCs24,25 
Type C Freud’s adjuvant, 
nanoparticles, toxin-derived 
adjuvant, flagellin 
Enhancing signal, co-stimulatory molecular, a novel super agonist, 
directly stimulating T cells, inducing cytokine storm26 
 
3.1.4 Introduction to adjuvants 
Adjuvants are materials that can improve immune responses. This adjuvant idea 
was first recognized by William Coley who employed bacterial products to treat cancer 
patients.3 Typically, there are three types of adjuvants (Table 3.1). MPLA (formulated in 
AS04) is a type A adjuvant that stimulates TLR4 signal pathway and triggers a polarized 
Th1 response and has been approved for clinical application in Europe.27,28  
Currently, there are four licensed adjuvants in human clinical application: Alum, 
MF59, AS03, and AS04.29 Despite that these adjuvants have been widely utilized in clinic 
(Table 3.2), there is still an urgent need of new adjuvants for usage with relatively 
immunologically challenging vaccine, such as cancer vaccines. More importantly, new 
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adjuvants are needed for the design and development of novel constructs of vaccines. 
There are also commercial adjuvants, such as Freund’s complete/incomplete adjuvant 
(CFA/IFA), Titermax Gold adjuvant, QS21 and so on, which are widely used in animals 
and in research laboratories but not in human.27  
Table 3.2 Licensed adjuvants28,30 
Adjuvant Immune active 
component 
Pattern recognition 
receptors (PRRs) 
Major immune 
response 
Vaccine 
Alum Aluminum salts NLRPs inflammasome Ab. Th2(mice) Ab. 
Th1+Th2 (humans) 
Various 
MF59 Squalene in emulsion of 
oilwater 
Pro-inflammatory 
responses 
Ab. Th1+Th2 Influenza/ 
pandemic flu 
AS03 Squalene in emulsion of 
oil-water + a tocopherol 
Pro-inflammatory 
responses  
Ab. Th1+Th2 Pandemic 
influenza 
AS04 MPL +Alum TLR4+NLRP3 
inflammasome 
Ab. Th1 HBV (Fendrix), 
HPV (Cervarix) 
Liposomes Oil-water emulsion   HAV, Flu 
Ab: antibodies; Alum: aluminum hydroxide; AS03: Adjuvant System 03; AS04: Adjuvant System 04; HBV: 
hepatitis B virus; HPV: human papillomavirus; MPL: monophosphoryl lipid A; NLRP3: nucleotide-binding 
oligomerization domain, leucine-rich repeat and pyrin domain containing 3; Th: helper cells; TLR4: Toll-like 
receptor 4.  
3.1.5 MPLA-based full-synthetic vaccine 
In addition to the advantages of semi-synthetic glycoconjugate vaccine described 
in chapter 1, full-synthetic vaccines with a well-defined structure have more improvements. 
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Firstly, glycan-protein conjugates usually have non-consistent loading of saccharides 
which induces the difficulties in quality control. But the full-synthetic vaccines will have 
consistent composition. In addition, the protein conjugates always need adjuvant for 
stimulating the immune response, while the full-synthetic vaccines could have a built-in 
adjuvant which will be more convenient to preparation and be further improved in vaccine 
design. With the help from the technology of organic synthesis, the full-synthetic vaccines 
have much stronger potential to provide immunological prevention against diseases.  
Therefore, based on the direction of full-synthetic vaccine, one of our research 
projects has focused on the development of fully synthetic TACA-based cancer vaccines 
using MPLA as a carrier. We have been interested in MPLA as a carrier because of its 
attractive immunostimulatory properties. We anticipated that MPLA would be able to not 
only improve the immunogenicity of tumor-associated carbohydrate antigens used for 
vaccine development but also act as a built-in adjuvant to formulate self-adjuvanting 
vaccines. The new vaccine design was to have the carbohydrate antigen linked to the 
non-reducing end of MPLA through a spacer as shown in Figure 3.4. 
 
Figure 3.4 A new construct of full-synthetic vaccine based on MPLA 
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In our previous investigation, a MPLA analog of the lipid A structure derived from 
Neisseria meningitides, was coupled to a GM3 antigen, which is overexpressed on 
melanoma cancer cell surface, and its synthetic analog N-phenylacetyl GM3 
(GM3NPhAc).31,32 The resulting conjugates, such as the MPLA-GM3NPhAc conjugate 
illustrated in Figure 3.5, were evaluated as vaccines that can be used for cancer 
immunotherapy based on cell surface sialic acid metabolic engineering.31,33-37 It was 
revealed that these conjugates alone could induce robust immune responses in animals 
in the absence of an external adjuvant (Figure 3.5), suggesting that, as an 
immunostimulant, MPLA was functional not only as a vaccine carrier but also as a built-
in adjuvant.31  
 
Figure 3.5 The structure of MPLA-GM3NPhAc and immune results.  
Encouraged by the above interesting discoveries, the present work aimed at: (1) 
further optimizing the lipid A structure as a vaccine carrier and built-in adjuvant, thus a 
series of MPLA derivatives were designed and synthesized for systematic structure-
activity relationship analysis in the context of conjugate vaccines, and (2) developing new 
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fully synthetic carbohydrate-based anticancer vaccines with the optimized lipid A as the 
carrier molecule.  
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3.2 Evaluation of MPLA-sTnNPhAc Conjugates as Cancer Vaccines and 
Optimization of the MPLA Structure as a Vaccine Carrier 
3.2.1 Introduction 
Sialyl-Tn (sTn, Figure 3.6) is a mucin-associated carbohydrate antigen that is 
overexpressed by a variety of tumors, such as breast, prostate, colorectal, ovarian, gastric 
and pancreatic carcinoma rather than normal cells,38-54 and it is relatively cancer-specific 
as it is rarely expressed on normal cells. In addition, the expression of sTn antigen is an 
independent indicator for cancer diagnosis.39,41,43 Moreover, sTn antigen is a predictor of 
metastatic potential which associates with more aggressive cancer status in breast 
cancer.38,39 Therefore sTn is an attractive target for anti-cancer vaccine and 
immunotherapy development. In 2003, a semi-synthetic cancer vaccine, Theratope®, 
was developed by Biomira Inc., which had the sTn antigen linked to keyhole limpet 
hemocyanin (sTn-KLH conjugate). This vaccine was successful in phase I and II clinical 
trials with excellent results in stimulating antibody- and cell-mediated immune responses 
against the tumor-associated antigen, but eventually failed in phase III clinical trial, 
because it eventually failed to induce robust immune responses in cancer patient.55-61  
 
Figure 3.6 The structure of sTn antigen 
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Inspired by the results of MPLA-GM3 conjugates31, here we have designed and 
synthesized four monophosphoryl analogs (including one from previous exploration) of 
the lipid A of N. meningitides, containing lipids of different chain lengths and linkages as 
well as different patterns of lipidation (Figure 3.7). To investigate the immunological 
properties of these MPLA derivatives as vaccine carriers and adjuvants, we conjugated 
them with N-phenyl acetyl sTn (sTnNPhAc), a modified TACA that can be further used in 
our immunotherapy strategy based on glycoengineering, and examined in mice the 
specific immune responses induced by the resulting MPLA-sTnNPhAc conjugats 3.1-3.4 
(Figure 3.7). Through these studies, we anticipated to identify novel vaccine carriers and 
adjuvants with improved immunological properties useful for the development of fully 
synthetic glycoconjugate cancer vaccines. 
 
Figure 3.7 The structures of designed MPLA derivatives and their sTn conjugates.  
3.2.2 Results and Discussion 
Immunological investigation of the MPLA-sTnNPhAc conjugates 3.1-3.4 was 
carried out with female C57BL/6J mouse, a well-characterized inbred strain for vaccine 
60 
 
evaluation and comparable to the human in immune reactions.62 To improve the solubility 
of these conjugates in buffer, they were incorporated in liposomes formed by using 1, 2-
distearoyl-sn-glycero-3-phosphocholine and cholesterol. Delivering glycoconjugate 
vaccines in liposomal forms can further improve their immunogenicity.63,64 For 
immunization, the liposomal preparations of 3.1-3.4 were each injected subcutaneously 
(s.c.) to a group of six mice. In the meantime, groups of mice were simultaneously 
inoculated with emulsions of 3.1-3.4 liposomes and Titermax Gold adjuvant to evaluate 
the potential influence of an external adjuvant on the activities of these glycoconjugate 
vaccines. The adopted vaccination schedule was to inject into each mouse 0.1 mL of a 
vaccine preparation containing ca. 3 µg of sTnNPhAc on day 1, 14, 21 and 28, 
respectively. Each mouse was subjected to bleeding on day 0 before the first injection 
(used as blank controls) and on day 27 and 38 after immunization. The blood samples 
were treated according to standard protocols to prepare antisera for the analysis of 
sTnNPhAc-specific antibodies by enzyme-linked immunosorbent assay (ELISA) with the 
human serum albumin (HSA) conjugate of sTnNPhAc (sTnNPhAc-HSA)35 as a capture 
antigen. In addition to total antibodies, antibody isotypes such as IgG1, IgG2a, IgG3 and 
IgM were also individually assessed. Antibody titers were calculated from linear 
regression analysis of the curves of the optical density (OD) value against serum dilution 
number, and were defined as the dilution number yielding an OD value of 0.2.31 
The ELISA results of antisera obtained with 3.1 without the use of an external 
adjuvant (Figure 3.8A) revealed that the conjugate itself provoked a strong sTnNPhAc-
specific immune response in mice. More importantly, in addition to IgM antibody, a high 
titer of IgG3 and some IgG1 antibodies were also observed, suggesting a T cell-
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dependent immune response.65,66 Interestingly, 3.1 plus Titermax Gold failed to stimulate 
a significant antibody response (Figure 3.8B), although IgM antibodies were observed. 
These results suggest that the external adjuvant had an inhibitory effect on the T cell-
mediated immune response against 3.1 but a relatively small influence on the B cell 
response. The results agreed well with our previous report about other MPLA-TACA 
conjugates.31  
The ELISA results of 3.2 (Figure 3.8C and 3.8D) were similar to that of 3.1 in terms 
of the type of immune responses provoked and the influence of Titermax Gold. However, 
the IgM and IgG antibody titers for 3.2 were much higher than that for 3.1. Moreover, 3.2 
stimulated a strong immune response in all of the mice. Another interesting finding was 
that 3.2 also induced a significant level of IgG1 antibody which is usually observed with 
neoglycoprotein vaccines. The ELISA results of 3.3 (Figure 3.8E and 3.8F) and 3.4 
(Figure 3.8G and 3.8H) were similar to that of 3.1 and 3.2, but their antibody titers were 
lower than that of 3.2 and higer than that of 3.1. In all of these cases, Titermax Gold 
showed inhibition of immune responses against the conjugate vaccines.  
 
   
62 
 
  
Figure 3.8 ELISA results of day 38 antisera of mice immunized with 3.1 alone (A), 3.1 
plus Titermax Gold (B), 3.2 alone (C), 3.2 plus Titermax Gold (D), 3.3 alone (E), 3.3 plus 
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Titermax Gold (F), 3.4 alone (G) and 3.4 plus Titermax Gold (H), respectively. The titers 
of various sTnNPhAc-specific antibodies are displayed. Each dot represents the antibody 
titer of an individual mouse, and the black bar shows the average antibody titer of a group 
of six mice.  
 
To further verify that the detected antibodies were indeed sTnNPhAc-specific, a 
competitive ELISA experiment for the pooled mouse antisera obtained with 3.2, 3.3, 3.4 
and 3.2 plus adjuvant was performed. In this study, various concentrations (0, 0.00152, 
0.0152, 0.152, 1.52, 15.2 and 152 µM) of free sTnNPhAc were added to compete with 
sTnNPhAc-HSA attached to the ELISA plate for antibody binding. Again, alkaline 
phosphatase-linked goat anti-mouse kappa antibody was employed as the secondary 
antibody. The OD values at 405 nm reflected the levels of total antibodies bound to the 
sTnNPhAc-HSA-coated plates. These studies (Figure 3.9) have revealed that sTnNPhAc 
had concentration-dependent inhibition of antibody binding to the plates and that, at 
concentrations higher than 152 µM, sTnNPhAc could essentially completely inhibit the 
binding, proving that the elicited antibodies were indeed specific to the sTnNPhAc antigen.   
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Figure 3.9 Competitive ELISA results of the pooled mouse antisera obtained with 
conjugates 3.2, 3.3, 3.4 and 3.2 plus adjuvant. The OD values at 405 nm reflected the 
levels of total antibodies bound to the sTnNPhac-HSA-coated ELISA plates in the 
presence of specified concentrations of sTnNPhAc.  
 
The above ELISA results disclosed that the MPLA conjugates 3.1-3.4 alone, that 
is, in the absence of any external adjuvant, provoked a robust antigen-specific immune 
response in mice. More importantly, they stimulated high titers of IgG3 and IgG1 
antibodies, indicating a T cell-mediated immune response desirable for cancer 
immunotherapy.65,66 Therefore, all of the synthetic MPLA derivatives could act both as a 
vaccine carrier and as an adjuvant to effectively enhance the immunogenicity of 
sTnNPhAc and to efficiently promote a T cell-dependent immune response toward 
TACAs.20,31,67 These properties of MPLA should be particularly useful for the design and 
development of new fully synthetic carbohydrate-based conjugate vaccines.  
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Titermax Gold is a commercial adjuvant that is commonly used with vaccines such 
as carbohydrate-protein conjugates37 to improve their immunogenicity. However, we 
showed in this work that it had an inhibitory impact on the immunological activities of 3.1-
3.4. As Titermax Gold mainly affect the T cell-mediated immune response. We proposed 
that Titermax Gold might interact with MPLA in the conjugate vaccine to prevent MPLA 
from binding to cell surface TLRs and affect its engagement in T cell-mediated 
immunological pathways. Another hypothesis is that Titermax Gold might interact with 
MPLA to affect vaccine delivery to the lymph system or antigen presenting cells (APCs) 
required for effective T cell-mediated immunity.68,69 This discovery and further detailed 
studies may help understand vaccine adjuvants, such as their binding sites, functional 
mechanisms and so on.  
Despite the fact that 3.1-3.4 stimulated similar patterns of immune responses in 
mice, they did show differences in immunological activity. For example, conjugate 3.2 
elicited much higher and more consistent titers of both total antibodies and IgG2 antibody 
than 3.1, 3.3 and 3.4 (Figure 3.9). Moreover, all of the mice showed strong immune 
responses to 3.2 but not to other conjugates. Clearly, 3.2 was the best vaccine among 
the MPLA conjugates investigated.  
Structurally, 3.1-3.4 were different only in their MPLA moiety, and their antisera 
were obtained by means of the same immunization protocol and schedule. Consequently, 
any difference in their immunological activity should reflect the impact of the MPLA 
structure. Conjugate 3.2 contained the monophosphoryl form of natural lipid A of N. 
meningitides (H44/76 strain).70 In 3.1, the two free hydroxyl groups on the lipid chains of 
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the MPLA moiety were removed; 3.3 and 3.4 were different in that their MPLA contained 
different lengths and different numbers of lipid chains than that of 3.2.  
As all these conjugates had essentially the same immunological profile, it seems 
that the free hydroxyl groups on the lipid chains and the length and number of lipid chains 
of MPLA had a quantitative, rather than qualitative, impact on its biological activities. As 
discussed in 3.1.2 with Figure 3.3, it is clear that the hydroxyl groups on the lipid chains 
play an important role in the lipid A interaction with its receptors so that the endotoxin of 
lipid a has a reduce factor about 10 comparing with natural form. Although the level of 
antibody titers is not exactly the same as the endotoxin activities of MPLA, the decreasing 
trend of immunostimulatory activity of MPLA in conjugate 3.1 compared with that in 3.2 
agrees with the trend of lipid A’s endotoxin activities. Additionally, elongating the length 
of lipids at the 3-O- and 3’-O- positions (conjugate 3.3) seem to have a relatively small 
impact, although such changes did result in reduced immunological activity and some 
inconsistence of immune responses in individual mice. Usually, as described in 3.1.2, 
lessened or additional one lipid chains linked to these lipids have a reduced impact of 
endotoxin activities about 102.2 What’s more, lipid A totally loses its endotoxin activity to 
be a LPS antagonist if two lipid chains are removed.4 In our case, the additional two lipid 
chains linked to these lipids as an octa-lipid chains MPLA is not like tetra-lipid chains one 
that loses immunological activity, but helps to elicit a considerable high level of antibody 
titers (conjugate 3.4) which only a little lower than that of 3.2.  
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3.2.3 Conclusion 
In summary, four MPLA derivatives were coupled with sTnNPhAc to form fully 
synthetic glycoconjugate cancer vaccines. Studies on the resulting MPLA-sTnNPhAc 
conjugates revealed that they elicited strong and T cell-dependent immune responses 
without the use of any external adjuvant. Our previous work revealed that antisera derived 
from mice immunized with MPLA conjugates could effectively bind to and kill cancer cells 
metabolically engineered to express the corresponding antigen.31 MPLA has thus been 
demonstrated to be a useful platform for the development of new vaccine carriers and 
adjuvants and for the development of novel types of fully synthetic carbohydrate-based 
cancer vaccines with self-adjuvanting properties. Our results have also revealed that 
MPLA derivatives containing six lipid chains exhibited more potent immunostimulatory 
activities than those with eight lipid chains (conjugate 3.4) and that the lipid structure and 
length had a significant impact on the immunology of MPLA. The monophosphoryl form 
of natural N. meningitides lipid A was found to have the most promising immunological 
properties and its sTnNPhAc conjugate elicited the most potent and the most consistent 
T cell-dependent anti-sTnNPhAc immunity. As a result, the MPLA moiety in 3.2 was 
identified as the first generation of optimized vaccine carriers and adjuvants that is under 
further optimization and additional investigation.  
On the other hand, Titermax Gold was found to inhibit the immunological activity 
of MPLA-sTnPhAc conjugates, whereas it has the opposite influence on the activity of 
protein-sTnNPhAc conjugates.33,35 It is proposed that Titermax Gold may interact with 
MPLA to affect its binding to cell surface receptors and/or its delivery to the lymph system 
or antigen presenting cells. It is anticipated that these issues may be clarified by studies 
68 
 
utilizing labeled MPLA derivatives and conjugates, the results of which should be useful 
for understanding the immunostimulatory and adjuvant activities and the functional 
mechanisms of MPLA and Titermax Gold, which is a very important topic in cancer 
vaccine immunology.  
 
3.2.4 Experimental Section 
Materials, Reagents, and Animals 
Glycoconjugates 3.1, 3.2, 3.3 and 3.4 conjugates were synthesized by Mohabul 
Mondal. STnNPhAc-HSA conjugate were synthesized according to the procedures 
previously reported by our laboratory. Titermax Gold adjuvant, 1, 2-distearoyl-sn-glycero-
3-phosphocholine, and cholesterol were purchased from Sigma-Aldrich. The SKMEL-28 
and B16F0 cancer cell line, Dulbecco’s Modified Eagle’s Medium (DMEM) for cell culture, 
and fetal bovine serum (FBS) were purchased from American Type Culture Collection. 
Penicillin-streptomycin and trypsin-EDTA were purchased from Invitrogen.  
Alkaline phosphatase linked goat anti-mouse kappa, IgM, IgG1, IgG2a, and IgG3 
antibodies and FITC-labeled goat anti-mouse kappa antibody were purchased from 
Southern Biotechnology. Female C57BL/6 mice of 6-8 weeks age used for immunological 
studies were purchased from the Jackson Laboratory.  
General Procedure for the Preparation of Liposomes of Glycoconjugates 3.1-3.4  
The mixture of a specific MPLA conjugate 3.1-3.4 (60 μg of sTnNPhAc moiety, 
0.102 μmol), 1, 2-distearoyl-sn-glycero-3-phosphocholine (M.W. 790.15, 0.52 μg, 0.664 
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μmol), and cholesterol (M.W. 386.66, 0.197 μg, 0.51 μmol) (a 10:65:50 molar ratio) was 
dissolved in CH2Cl2 and MeOH (1:1, v/v, 2 mL) in a 10 mL vial. Then, the solvents were 
removed in vacuum to form a thin lipid film on the vial wall, which was hydrated by adding 
2.0 mL of HEPES buffer (20 mM, pH 7.5) containing NaCl (150 mM) and shaking the 
mixture in 40 ⁰C water bath, and then shaking it by vortex mixer for several times to form 
a milky suspension. The milky suspension was finally sonicated for 1 min to obtain the 
desired liposomes.  
General Procedure for the Preparation of Emulsion of liposomes and Adjuvant 
The prepared liposomes with double concentration were mixed with Titermax Gold 
adjuvant (1:1, v/v) and to form an emulsion according to the manufacturer’s protocol.  
Immunization of Mouse  
Each group of six female C57BL/6 mice were immunized on day 1 by 
subcutaneous (sc) injection of 0.1 mL of the liposomal solution of a specific 
glycoconjugate 3.1-3.4 containing 3 μg of the carbohydrate antigen (5.1 nmol) or by 
injection of an emulsion of the liposomal solution of a specific glycoconjugate vaccine and 
Titermax Gold adjuvant prepared according to the manufacturer’s protocol (each 1 mL of 
the liposomal solution mixed with 1 mL of Titermax Gold adjuvant). Following the initial 
immunization, mice were boosted 3 times on day 14, day 21 and day 28 by sc injection 
of the same conjugate and by the same immunization protocol. Blood samples of each 
mouse were collected through the leg veins prior to the initial immunization on day 0 and 
after immunization on day 27 and day 38 and were clotted to obtain antisera that were 
stored at -80 ⁰C before use.  
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Protocols for ELISA 
ELISA plates were treated with 100 μL of a solution of sTnNPhAc-HAS conjugate 
(2 ug/ml) dissolved in coating buffer (0.1 M bicarbonate, pH 9.6) at 4 ⁰C overnight, and 
then at 37 ⁰C for 1 h, which was followed by treatment with blocking buffer (10% BSA in 
PBS solution with NaN3) and washing 3 times with phosphate-buffered saline (PBS) 
containing 0.05% Tween-20 (PBST). Thereafter, a pooled or an individual mouse 
antiserum with serial half-log dilutions from 1:300 to 1:656100 in PBS was added to the 
coated ELISA plates (100 μL/well), which was followed by incubation at 37 ⁰C for 2 h. The 
plates were then washed with PBS and incubated at rt for another 1 h with a 1:1000 
diluted solution of alkaline phosphatase linked goat anti-mouse kappa, IgM or IgG2a 
antibody or with a 1:2000 diluted solution of alkaline phosphatase linked goat anti-mouse 
IgG1 and IgG3 antibody (100 μL/well), respectively. Finally, these plates were washed 
with PBS and developed with 100 μL of p-nitrophenylphosphate (PNPP) solution (1.67 
mg/mL in buffer) for 30 min at rt, followed by colorimetric readout using a BioRad 550 
plate reader at 405 nm wavelength. The optical density (OD) values were plotted against 
antiserum dilution values, and a best-fit line was obtained. The equation of the line was 
employed to calculate the dilution value at which an OD of 0.2 was achieved, and the 
antibody titer was calculated at the inverse of the dilution value.  
Protocols for Competitive ELISA 
The protocols for competitive experiment had the same process as ELISA of 
antibody investigation described above. The only difference was that free sTnNPhAc 
saccharide was added to compete with antibody binding of plate-bound sTnNPhAc-HSA. 
Hence, the ELISA plate was coated with sTnNPhAc-HSA in 4 ⁰C overnight and then 
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incubated in 37 ⁰C for 1 h. After washed with PBS buffer, the plate was treated with 
blocking buffer in rt (room temperature) for 1 h. After that, the plate was washed with PBS 
and then, added 50 μL PBS solution containing 0, 0.003, 0.03, 0.30, 3.0, 30.4 and 304 
μM of free sTnNPhAc and 50 μL of pooled antisera (1:150 dilutions) in PBS to each well 
(the final concentrations of free sTnNPhAc were 0, 0.0015, 0.015, 0.15, 1.5, 15.2 and 152 
μM in 1:300 diluted pooled antisera solution) at the same time, and incubated in 37 ⁰C for 
2 h. Then, the plate was washed and incubated with alkaline phosphatase linked goat 
anti-mouse kappa antibody (1:1000 dilution), washed, reacted with PNPP solution and 
finally collected the reading at 405 nm as described above.31 
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3.3 MPLA Carrier Applied in Globo H-Based Vaccine 
3.3.1 Introduction 
Globo H (GH) is a hexasaccharide specifically overexpressed on a number of 
cancer cells, such as breast, lung, ovary, stomach and small-cell lung cancer cells but 
weakly expressed on normal cells.71-76  It was first discovered from human breast cancer 
cell line MCF-7 in 1983 by Hakomori.77-79 The structure of Globo H is showed in Figure 
3.10 which was first assigned by Hakomori80 and colleagues and was fully synthesized 
by several groups.79,81-84  The immunocharacterization of Globo H attracted interests in 
this antigen which was studied via the monoclonal antibodies (mAb) MBr1 and VK9.78,85  
As a TACA described before, Globo H is an attractive target for the development 
of an immunotherapy and anti-cancer vaccines against a variety of cancer such as breast 
carcinoma, small-cell lung carcinoma, and several malignant cancers. Base on the 
structure of Globo H, a therapeutic cancer vaccine, full-synthetic Globo H conjugated to 
keyhole limpet hemocyanin (KLH) with adjuvant QS-21, against breast and prostate 
cancer, showed hopeful results in clinical trials.79,83,86  This vaccine was now in Phase III 
clinical trial with Globo H synthesized by the one-pot method.84 
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Figure 3.10 Structure of Globo H 
 
To further improve the efficiency of Globo H conjugated vaccine, in Chi-Huey 
Wong’s group, Globo H was conjugated to different carrier proteins including KLH, 
diphtheria toxoid cross-reactive material (CRM) 197 (DT), tetanus toxoid (TT), and BSA 
with the combination of various adjuvants such as QS-21 and α-galactosylceramide 
C34.81 The results showed that, compared with the phase III clinical trial vaccine, Globo 
H-KLH, the Globo H-DT with C34 adjuvant vaccine elicited higher antibody titer of IgG 
isotype which has high selectivity for not only Globo H but also the Globo H related 
epitopes, including stage-specific embryonic antigen 3 (SSEA3) and SSEA4. In additional, 
they developed a novel vaccine candidate, SSEA4-DT with C34 adjuvant, which can 
stimulate strong immune response with high IgG antibodies which are highly specific for 
SSEA4 antigen.81 
In our group, Globo H was successfully synthesized which can be further linked 
with carriers as anti-cancer vaccine. Based on the previous investigation, MPLA showed 
excellent characteristics as a build-in carrier and adjuvant. Therefore, the MPLA was 
applied in Globo H-based anti-cancer vaccine design. The structure of Globo H-KLH (3.6) 
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and Globo H-MPLA (3.7) were showed in Figure 3.11.This Globo H-MPLA conjugate 
contains the MPLA moiety which is the structure used in conjugate 3.2 which has the best 
result in our above evaluation.87  
 
Figure 3.11 The structure of Globo H-KLH (3.6) and Globo H-MPLA (3.7) 
3.3.2 Results and Discussion 
Immunological investigation of Globo H-KLH (3.6) and Globo H-MPLA (3.7) 
conjugates was carried out with female C57BL/6J mouse. The KLH conjugate was 
dissolved in PBS solution and then mixed with Freund’s complete adjuvant (CFA) as an 
emulsion to immunize mice. To improve the solubility of the MPLA conjugate and also 
improve the immunogenicity of vaccine, the MPLA conjugate was incorporated in 
liposomes formed by using 1,2-distearoyl-sn-glycero-3-phosphocholine and cholesterol 
the same as described in previous MPLA-sTnNPhAc conjugate project.63,64 For 
immunization, the adjuvant preparation of 3.6 and the liposomal preparation of 3.7 was 
injected subcutaneously (s.c.) to a group of six mice. The inoculation schedule was to 
inject into each mouse 0.1 mL of a vaccine preparation containing ca. 3 µg of Globo H 
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moiety on day 1, 14, 21 and 28, respectively. The blood of each mouse was collected on 
day 0 before the first inoculation (used as blank controls) and on day 27 and 38 after 
immunization. The blood samples were used to prepare antisera according to the protocol. 
Then the antisera were further analyzed by ELISA the same as previous described in 
MPLA-sTnNPhAc project. Globo H-HSA was used as capture reagent, and goat anti-
mouse antibodies with AP enzyme were used as second antibodies. The total antibody 
titer and the antibody titers of each isotype, IgG1, IgG2a, IgG2b, IgG3 and IgM were 
calculated from the curves of the optical density (OD) value against serum dilution number, 
and the titers were defined as the dilution number yielding an OD value of 0.1.31,87  
The ELISA results of antisera induced by 3.6 with CFA as an external adjuvant 
(Figure 3.12) indicated that Globo H-KLH (3.6) conjugate provoked a strong Globo H-
specific antibody response (kappa: about 38,000) in mice. Moreover, the high antibody 
titer (average about 35,000) of IgG1 and some positive antibody titer of IgG2b and IgG3 
suggested that T cell-dependent immunity was involved. Generally, six out of six mice 
had strong Globo H specific antibody titers which means every mouse had been 
immunized successfully. In addition, five out of six mice had high IgG1 antibody titer.  
The ELISA results of antisera elicited by Globo H-MPLA (3.7) had similar antibody 
response (the average total antibody titer was about 60,000) including high antibody titer 
of IgG1 isotype ( about 64,000) which indicated that Globo H-MPLA (3.7) had excellent 
immunogenicity to stimulate immune response especially T cell immunity. Excitingly, the 
total antibody and IgG1 isotype of Globo H-MPLA (3.7) had even higher antibody titer 
than that elicited by Globo H-KLH (3.6) conjugate. Additionally, five out of six mice (one 
had 8741 much lower than others) in this group had been successfully immunized by 
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conjugate 3.7 indicated by the high kappa antibody titer. And, five out of six mice (one 
had low antibody titer 3853) in this group had high antibody titer of IgG1 isotype. 
 
Figure 3.12 ELISA results of day 38 antisera of mice immunized with 3.6 plus CFA 
adjuvant (A) and 3.7 in liposome form (B), respectively. The titers of Globo H specific 
antibodies are displayed. Each dot represents the antibody titer of an individual mouse, 
and the black bar shows the average antibody titer of a group of six mice.  
 
These results suggested that the MPLA conjugate had an excellent potential for 
design as a build-in adjuvant and carrier. This phenomenon was discovered here that a 
small molecule vaccine can work as well as large molecule vaccine with protein carrier. 
What’s more, the protein carrier usually with T cell epitopes can help provoked T cell 
immunity like the results here provoked by Globo H-KLH (3.6) (Figure 3.12). However, in 
our new discovery, MPLA, usually considered as a TLR-based adjuvant,18,19 can serve as 
a stimulator to elicit T cell-mediate immunity as well.  
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Figure 3.13 The kinetic ELISA results of antisera induced by conjugates 3.6 and 3.7. 
ELISA results of Globo H-specific antibody in the antisera pooled from mice immunized 
with (A) conjugate 3.6 plus CFA adjuvant and (B) 3.7 in liposome form, respectively, on 
day 21 (blue line), day 27 (red line) and day 38 (green line). X-axis is the diluted factor 
from 300 to 8100 in logarithmic scale, and y-axis is the OD value at 405 nm reading each 
well after 30 min PNPP reaction. (C) Calculated antibody titer of pooled antisera obtained 
from mice immunized with 3.7 in liposome form on day 0, day 14, day 21, day 27 and day 
38.  
 
The time courses of the induction of total antibody pooled from six mice immunized 
by 3.6 or 3.7 were shown in Figure 3.13. The antibody titers generally increased with the 
more immunization boost. Day 27 antisera were obtained after three boosts and day 38 
were obtained after four boosts. Three boosts of conjugates both 3.6 and 3.7 can already 
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elicit significant immune response. The fourth boost could improve the immune response 
significantly, nearly twice higher than day 27 result. Therefore, both the vaccines required 
four times immunization injection.  
Cell surface reactivity of these antisera obtained from mice immunized with 3.6 
plus CFA adjuvant or 3.7 in liposome form was evaluated by fluorescence-activated cell 
sorting (FACS) technology on Globo H positive MCF-7 cell line (Figure 3.14) and Globo 
H negative SKMEL-28 cell line as a negative control (Figure 3.15). In these studies, both 
kinds of cells were incubated with normal mouse sera or pooled antisera obtained from 
mice immunized with 3.6 or 3.7, respectively. Thereafter, the cells were cultured with 
fluorescein isothiocyanate (FITC)-labeled goat anti-mouse kappa antibody, followed by 
FACS analysis. 
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Figure 3.14 FACS results of MCF-7 cells. (A) MCF-7 cell without any treatment; (B) MCF-
7 cells stained with normal sera and FITC labeled 2nd antibody; (C) MCF-7 cells stained 
with antisera obtained from mice immunized with 3.6 plus CFA adjuvant; (D) MCF-7 cells 
stained with antisera obtained from mice immunized with 3.7 in liposome form; (E) Gated 
cells percentage of positive cells and (F) Mean fluorescent intensity of cells stained with 
normal sera and the other two antisera.  
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Figure 3.15 FACS results of SKMEL-28 cells. (A) SKMEL-28 cell without any treatment; 
(B) SKMEL-28 cells stained with normal sera and FITC labeled 2nd antibody; (C) SKMEL-
28 cells stained with antisera obtained from mice immunized with 3.6 plus CFA adjuvant; 
(D) SKMEL-28 cells stained with antisera obtained from mice immunized with 3.7 in 
liposome form. 
 
 
Figure 3.16 Overlay plots of FACS results of MCF-7 (A) and SKMEL-28 (B) cell lines 
stained with normal sera (green), pooled antisera from mice immunized with 3.6 plus CFA 
adjuvant (blue) and 3.7 liposome (red), respectively.  
 
From the FACS results (Figure 3.16) of MCF-7 cell line and SKMEL-28 cell line 
which were stained with normal sera and antisera obtained from mice immunized with 
conjugate 3.6 and 3.7, the conclusion that both conjugate 3.6 and 3.7 can elicit strong 
immune response and Globo H-specific antibodies was further confirmed. The MCF-7 
cells with Globo H expressed on cell surface can be significantly stained with the antisera 
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containing Globo H-specific antibodies, while the SKMEL-28 cell had negative results. 
What’s more, the gated cells percentage of positive cells of antisera induced by 3.7 was 
significantly higher than that of antisera induced by 3.6 plus CFA adjuvant. This 
phenomenon suggested that 3.7 conjugates may have better immunological 
characteristics than that of conjugate 3.6 which was consistent with the results of ELISA. 
In addition, the MFI of cells stained with antisera induced by 3.7 are significantly higher 
than that of 3.6 which further confirmed the results of ELISA and gated cells percentage. 
Therefore, both ELISA and FACS results confirmed that both conjugates can elicit strong 
immune response and MPLA conjugate 3.7 may have even better results than KLH 
conjugate 3.6.  
 
3.3.3 Conclusion 
In summary, both Globo H-KLH and –MPLA conjugates can provoke strong Globo 
H-specific immune response, especially the T cell immunity. Moreover, Globo H-MPLA 
was proved that have better capability to generate antibodies than that of KLH conjugate. 
It’s the first time we discovered that small molecular glycoconjugate with MPLA carrier 
had better immunological capability than that of glycoprotein. Although the mechanism of 
how MPLA conjugate elicited stronger immune response was not clear, the MPLA-based 
new construct of vaccine really had charming immunological properties, such as external 
adjuvant-free and the ability of stimulate T cell-mediated immunity. Some of the Globo H-
KLH conjugate was already in phase III clinical trial for the therapy of breast and prostate 
cancers. Therefore, our new construct vaccine, Globo H-MPLA which showed better 
ELISA and FACS results than KLH conjugate, should have magnificent hope to be further 
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applied in clinical trial. For future directions, it is feasible and interesting to prepare Globo 
H-specific monoclonal antibodies (mAbs) using in the further immunotherapeutic studies. 
The improvement of the novel construct using MPLA as carrier is also another interesting 
direction. The construct may be promoted by coupling with other components, such as T 
cell epitopes, multivalent antigens and so on. What’s more, the successful strategy of 
vaccine designs with a TLR ligands also can be moved forward to other TLR ligands, 
lectin ligands and so on.  
 
3.3.4 Experimental Section 
Materials, Reagents, and Animals 
Glycoconjugates 3.6, 3.7 and Globo H-HSA were synthesized by Guochao Liao. 
Freund’s complete adjuvant (CFA), 1, 2-distearoyl-sn-glycero-3-phosphocholine, and 
cholesterol were purchased from Sigma-Aldrich. The MCF-7 and SKMEL-28 cancer cell 
line, Dulbecco’s Modified Eagle’s Medium (DMEM) for cell culture, and fetal bovine serum 
(FBS) were purchased from American Type Culture Collection (ATCC). Penicillin-
streptomycin and trypsin-EDTA were purchased from Invitrogen.  
Alkaline phosphatase (AP) linked goat anti-mouse kappa, IgM, IgG1, IgG2a, IgG2b 
and IgG3 antibodies and FITC-labeled goat anti-mouse kappa antibody were purchased 
from Southern Biotechnology. Female C57BL/6 mice of 6-8 weeks age used for 
immunological studies were purchased from the Jackson Laboratory.  
Protocol of vaccine preparation 
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The loading of Globo H-KLH is about 8%. According to KLH m.w. 350~400 kDa, 
each KLH molecule has 29~33 Globo H residents.  
Table 3.3 Dose of KLH conjugate 3.6 and MPLA conjugate 3.7 
Conjugate Globo H amount/ ug Globo H amount/nmol 1 Dose amout/µg  30 Dose/µg 
3.6 3 2.83 37.5 1125 
3.7 6 5.7 16 500 
 
Preparation of liposomes of glycoconjugates 3.7. The protocol was similar to that 
reported in the literature.31,87 Briefly, the mixture of a specific conjugate 3.7 (0.5 mg, 0.176 
μmol), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (0.872 mg, 1.1 μmol), and 
cholesterol (0.33 mg, 0.85 μmol) (in a 10:65:50 molar ratio) was dissolved in CH2Cl2, 
MeOH and H2O (about 3:3:1, v/v, 2 mL) in a vial. The solvents were then removed in 
vacuum to form a thin lipid film on the vial wall, which was hydrated by adding 3.0 mL of 
HEPES buffer (20 mM, pH 7.5) containing NaCl (150 mM) and shaking the mixture by 
vortex.  
Preparation of emulsion of KLH conjugate 3.6. The protocol was similar to that 
reported in the literature. Generally, conjugate 2 (1.125 mg) was dissolved in 1.5 mL 1X 
PBS solution and mixed with 1.5 mL Freund’s Complete Adjuvant (CFA) following the 
manufacturer’s protocol to form an emulsion.  
Immunization of mouse 
Each group of six female C57BL/6J mice were inoculated on day 1 by 
subcutaneous (s.c.) injection of 0.1 mL of the liposomal solution or CFA emulsion of a 
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specific glycoconjugate. Following the initial immunization, mice were boosted 3 times on 
day 14, day 21, and day 28 by s.c. injection of the same conjugate and by means of the 
same immunization protocol. Mouse blood samples were collected prior to the initial 
immunization on day 0 and after immunization on day 21, day 27 and day 38, and were 
clotted to obtain antisera that were stored at -80 °C before use. The animal protocol (#A 
02-10-14) for this investigation was approved by the Institutional animal Care and Use 
Committee (IACUC) of Wayne State University, and all animal experiments were 
performed in compliance with the relevant laws and institutional guidelines.  
ELISA protocol 
ELISA plates were treated with 100 μL of a solution of Globo H-HSA conjugate (2 
μg/mL) dissolved in coating buffer (0.1 M bicarbonate, pH 9.6) at 37 °C for 1 h, which was 
followed by treatment with a blocking buffer and washing 3 times with phosphate-buffered 
saline (PBS) containing 0.05% Tween-20 (PBST). Then, the pooled or an individual 
mouse antiserum with serial half-log dilutions from 1:300 to 1:656100 in PBS was added 
to the coated plates (100 μL/well) and incubated at 37 °C for 2 h. The plates were wased 
with PBST and incubated at rt for another hour with a 1:1000 diluted solution of alkaline 
phosphate (AP) linked goat anti-mouse kappa, IgG1, IgG2a, IgG2b, IgG3 and IgM 
antibody (100 μL/well), respectively. Finally, the plates were washed with PBST and 
developed with 100 μL of a p-nitrophenylphosphate (PNPP) solution (1.67 mg/mL in buffer) 
for 30 min, 1 h or 2 h (Due to the low reading, the longer reaction time made the reading 
higher; all groups will be compared in the same reaction condition) at rt for colorimetric 
readout using a microplate reader at 405 nm wavelength. For titer analysis, OD values 
were plotted against antiserum dilution values, and a best-fit logarithm line was obtains. 
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The equation of this line was used to calculate the dilution value at which an OD of 0.1 
(this value will be further modified according the data to get better plots) was achieved, 
and the antibody titer was calculated at the inverse of the dilution value.  
Protocols for FACS Assay 
MCF-7 cell line (which can expressed Globo H antigen) was chose to be performed 
this experiment, and SKMEL-28 cell line (which was confirmed that Globo H antigen 
negative) was chose to be as negative group. MCF-7 cell line was incubated in ATCC-
formulated Eagle's Minimum Essential Medium (EMEM) containing 10% FBS and 1% 
antibiotics. SKMEL-28 cell line was incubated in ATCC-formulated Dulbecco's modiﬁed 
Eagle's medium (DMEM) containing 10% FBS and 1% antibiotics.  
Then these cells were harvested by being treated with trypsin-EDTA solution. Cells 
(about 1.0 ×106) were washed twice with FACS buffer (PBS containing 5% FBS) and 
incubated with 50 µL of normal mouse sera (1:10 dilution) at 4 °C for 15 min. Then the 
cell were washed with FACS buffer and incubated with 50 µL certain pooled antisera of 
day 38 (1:10 dilution) at 4 °C for 30 min. After that, cells were washed again with FACS 
buffer and incubated with FITC-linked goat anti-mouse kappa antibody (2 µL in 50 µL 
FACS buffer) at 4 °C for 30 min. Finally, cells were washed and suspended in 0.8 mL of 
FACS buffer, and then sent to FACS analysis on a Becton Dickinson LSR II Analyzer.  
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CHAPTER 4 Development of Novel Carbohydrate-Based Vaccines against 
Haemophilus Influenzae Type B and Neisseria Meningitidis Serotype C 
 
4.1 Vaccines against Haemophilus Influenzae Type B  
4.1.1 Introduction 
Haemophilus influenzae type b (Hib) is an important human pathogen that can 
cause various diseases, such as bacterial meningitis and pneumonia, and it usually 
strikes children under the age of 5 years old. Before Hib vaccine available, bacterial 
meningitis caused by Hib was a life-threatening disease among young children. 
(www.cdc.gov/vaccines) Hib-caused disease have been under control in developed 
countries by the introduction of successful conjugate vaccines beginning from 1990s.1 
However, according to the estimation of the World Health Organization (WHO), Hib still 
remains a life-threatening disease in developing country that causes approximately three 
million serious illnesses and an estimation of 386,000 deaths per year among children 
under the age of 5 years old.2,3 (World Health Organization website (2005): 
http://www.who.int/mediacentre/factsheets/fs294/en/) 
It has been well known for many years that the capsular polysaccharide (CPS) of 
Hib, a polymer of repeating ribosyl ribitol phosphate (RRP) units4 (Figure 4.1), is an 
attractive target for developing vaccines against Hib. Currently, the commercial available 
Hib vaccines were made from the CPS extracted from bacteria by conjugation with carrier 
proteins such as tetanus toxoid (TT) (ActHib, 1993, Sanofi Pasteur; Hiberix, 1998, EU) 
and diphtheria toxoid (DT) (Pentacel, Sanofi Pasteur), which are protective against the 
diseases caused by Hib. 
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Figure 4.1 The structure of polyribosylribitol phosphate (RRP) on Hib surface.  
 
However, the Hib RRP polysaccharides used for vaccine production, which were 
isolated from the supernatants of bacterial cell cultures, are often heterogeneous and 
contaminated with other antigenic components that may cause safety problems and 
quality control problems. To deal with the issue, conjugate vaccines based on well-defined 
synthetic carbohydrate antigens have attracted great interest. After decades of 
development and optimization, the first semi-synthetic glycoconjugate vaccine against 
Hib, Quimi-Hib™ (Heber Biotech), which was derived from the conjugation of synthetic 
polyribosylribitol phosphate and tetanus toxoid (TT), was approved and commercialized 
in Cube and became a part of Cuba’s national vaccination program in 2004.5-7 This 
vaccine was also confirmed to stimulate higher long-term protective antibody titers than 
that of licensed products composed with polysaccharide extracted from Hib bacteria.5,6 
This research has provided a proof of principle for the development of effective bacterial 
vaccines based on oligosaccharides in addition to CPSs. The great success of Quimi-
Hib™ has encouraged the exploration of a series of vaccines against Neisseria 
meningitidis serogroup C8 and W1359  and Streptococcus pneumoniae10. 
Actually, as early as in 1990s, Peeters’ group already synthesized a series of Hib 
CPS derivatives, including trimeric and tetrameric RRP, and conjugated them to carrier 
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proteins such as DT and TT via a thioether linkage.11 Immunological studies indicated that 
all of these conjugates elicited RRP-specific antibody responses with an increasing 
IgG/IgM antibody ratio in both mice and monkeys. Moreover, the tetramer conjugates 
elicited higher RRP-specific antibody titers than the trimer conjugates, suggesting that the 
tetrameric RRP was a better immunogen. In addition, the results of adult monkeys 
immunized with tetrameric RRP-TT conjugate were as good as that of oligosaccharide-
CRM197 conjugate, which elicited protective levels of serum antibodies in human infants 
after two or three boosts.  
Additional investigation about synthetic RRP conjugate vaccine against Hib was 
carried out by Chong’s group.12 They coupled synthetic oligosaccharides carrying RRP 
repeating units to synthetic peptides, which contained potent T-helper cell determinants 
and B-cell epitopes of Hib outer membrane proteins (OMPs), P1, P2 and P6.  Animal 
studies of these conjugates revealed that some of them could elicit high titers of both 
RRP-specific and OMP-specific IgG antibodies. Moreover, they investigated the factors 
that might affect the conjugate immunogenicity. They found that the magnitude of RRP-
specific antibody responses significantly depended on the relative spatial orientations of 
RRP and T-cell determinants and that the antibody response increased when a multiple 
antigenic peptide carrier was used. It was found that three RRP repeating units were 
optimal to elicit RRP-specific antibodies. Lipidation of the peptide-RRP conjugates was 
found to have a minimal effect on the immune response.  
In conclusion, the above studies have clearly demonstrated that a carbohydrate 
hapten conjugated with a peptide can provoke strong immune response, and especially 
help elicit T cell-dependent immune response. Furthermore, the antisera raised by these 
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conjugates were confirmed to be protective against Hib infection in an infant rat model.   
4.1.2 Our Vaccine Designs 
The main aims of this project were to systematically explore the structure-activity 
relationships of oligo-RRP as antigens and develop effective RRP-based Hib vaccines.  
According to the literature, Hib-derived capsular polysaccharides used in some licensed 
vaccines can contain oligosaccharides as short as five RRP repeating units.13 Moreover, 
trimeric and tetrameric RRPs were demonstrated to have excellent immunostimulatory 
ability.11,12 For example, in Quimi-Hib™, the saccharide moiety has an average of eight 
RRP repeating units.5  
Based on the above discoveries, our group designed tri-, tetra- and pentameric 
RRPs, which were successfully synthesized by Dr. Guochao Liao, and linked them to KLH 
and MPLA to form conjugates 4.1-4.3 and 4.7-4.9 (Figure 4.2). In the meantime, these 
oligosaccharides were also coupled with HSA to get conjugates 4.4-4.6 that were utilized 
as the capture reagents in ELISA experiment. The new RRP-KLH conjugates 4.1-4.3 and 
RRP-MPLA conjugates 4.7-4.9 were evaluated as vaccines in mice. 
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Figure 4.2 The structure of designed olio-RRPs and their KLH conjugates (4.1-4.3), HSA 
conjugates (4.4-4.6), and MPLA conjugates (4.7-4.9) 
 
4.1.3 Results and Discussion  
4.1.3.1 KLH Conjugates 4.1-4.3 as Vaccines  
After the KLH conjugates 4.1, 4.2 and 4.3 and HSA conjugates 4.4, 4.5, and 4.6 
were synthesized, their weight% loadings of the saccharide moiety were examined, and 
the results were showed in Table 4.1. The saccharide loadings of HSA conjugates were 
estimated by means of MS.  In this case, the average molecular weights of HSA and HSA 
conjugates were obtained by MALDI TOF MS (Figure 4.3). Then, the saccharide loadings 
of were calculated according to the following equation: 
% saccharide loading = [conjugate MW - HSA MW]/conjugate MW 
where the HSA MW was 67 kDa. The calculated saccharide loadings of 4.4, 4.5 and 4.6 
were about 13.7%, 8.4% and 7.4%, respectively. Their saccharide loadings were also 
examined by a chemical method,14,15 which gave slightly different results, namely that the 
loadings of 4.4, 4.5 and 4.6 were about 8%, 8.6% and 9.6%, respectively. The differences 
may be caused by the systematic errors of the chemical method, in which the presence 
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of protein and the existence of saccharides in the form of conjugate might have some 
impacts on the carbohydrate analysis. Nevertheless, the results suggested that resultant 
glycoconjugates had the proper saccharide loadings as vaccines, as it has been observed 
that glycoconjugates with sugar loading in the range of 5-20% produce the optimal 
immunological results. For the KLH conjugates, as KLH is huge and exists in difficult 
forms, which makes its measurement by MS very difficult, their loadings were only 
examined by the chemical method.14,15 Their loadings were also in the acceptable range 
of 8~9%. 
 
Table 4.1 The loadings of saccharide moiety in protein conjugates*  
Conjugates Loading (wt %) 
Average saccharide 
residues per protein 
4.1 (Hepta-Sacc-KLH) 8.4 27 
4.2 (Nona-Sacc-KLH) 8.4 21.5 
4.3 (Undecyl-Sacc-KLH) 9.0 19.2 
4.4 (Hepta-Sacc-HSA) 7.88  (13.7)** 8 
4.5 (Nona-Sacc-HSA) 8.60  (8.4)** 3.7 
4.6 (Undecyl-Sacc-HSA) 9.57  (7.4)** 2.7 
* Data provided by Dr. Guochao Liao. 
**The values in () were calculated according to the MALDI TOF MS data (Figure 4.4). 
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Figure 4.3 MALDI TOF MS results of HSA conjugates 4.4, 4.5 and 4.6.  
 
Immunological evaluations of RRP-KLH conjugates 4.1-4.3 were carried out with 
female C57BL/6J mouse. For initial immunization, each KLH conjugate containing ca. 3 
µg of the carbohydrate antigen mixed with Titermax Gold adjuvant as an emulsion (0.1 
mL) was injected subcutaneously (s.c.) to each mouse in a group of six. Four more boost 
immunizations were carried out in these mice on day 14, day 21, day 28 and day 38, 
respectively, using the same vaccines.  
The immunological responses to conjugates 4.1-4.3 were evaluated by analyzing 
the antigen-specific antibody titers in the mouse sera by ELISA. For this purpose, each 
mouse was subjected to bleeding on day 0 before the initial injection (used as the blank 
control) and on day 27, day 38 and day 48 after immunization. The blood samples were 
treated to prepare sera according to standard protocols and the antisera were stored at -
80 °C before further analysis by ELISA with the corresponding HSA conjugates 4.4-4.6 
as capture antigens. Antibody titers were calculated from the logarithm fit of the curves of 
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the OD value against serum dilution number, and were defined as the dilution number 
yielding an OD value of 0.5.   
Kinetic results of the immune responses 
To investigate the changes in immune responses upon each boost immunization, 
we analyzed the total antibody (kappa) titers in the sera obtained at different date points. 
Figure 4.4 shows the antigen-specific total antibody titers of pooled sera. Clearly, all of 
the three conjugates elicited strong immune response after 4 boost immunizations, and 
the antibody titers of the day 48 antisera were significantly higher than that of day 38 
antisera. Most significantly, some of the conjugates, e.g. 4.2, did not stimulate strong 
responses until the 4th boost immunization. 
 
Figure 4.4  ELISA results of total antibodies (kappa) of the pooled antisera collected on 
day 0, day 38 and day 48 from mice immunized with: (A) 4.1 plus Titermax Gold adjuvant; 
(B) 4.2 plus Titermax Gold adjuvant; (C) 4.3 plus Titermax Gold adjuvant. (D) Calculated 
antigen-specific total antibody titers of the conjugates. 
 
It is worth pointing out that conjugate 4.2 was somehow not well soluble in 1X PBS. 
101 
 
The low antibody titer of 4.2 after first 3 boost immunizations might be due to this problem. 
Thereafter, the method to prepare vaccines for immunization was improved. The 
conjugates were first dissolved in 10X PBS (high ionic concentration can help the 
conjugates to dissolve) and then diluted to 2X PBS buffer, which were finally mixed with 
adjuvant.  Furthermore, for the initial and first 3 boost immunization, the route of vaccine 
administration was subcutaneous, but the 5th boost immunization was intramuscular. All 
these changes might have helped conjugate 4.2. 
In conclusion, conjugates 4.1-4.3 could elicit robust immune responses, and the 
induced immune responses were dependent on the frequencies of boost immunization. 
With the increase in the number of boost immunization, the immune responses became 
stronger. The results also suggested that immune responses might be dependent on the 
antigen structure, as the 3 conjugates were different. In addition, it seems that the 
preparation and administration methods of the vaccines also had some impact on the 
immune response, which is an interesting question worth further investigation.  
Isotypes of antibodies 
In addition to the total antibody titer which shows the overall immune response to 
a specific vaccine, we have also examined the titers of various antibody isotypes of the 
antiserum obtained with each vaccine to show the quality of the immune response. The 
ELISA results of day 48 antisera are depicted in Figure 4.5. Each dot represents the 
antibody titer of an individual mouse, and the black bar represents the average antibody 
titer of a group of six mice. It is evident that, in addition of IgM antibodies, all of the three 
conjugates 4.1-4.3 could elicit high levels of IgG1 antibodies, indicating the involvement 
of T cell-mediated immunity. In the case of 4.1 and 4.2, significant levels of IgG2a and 
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IgG3 antibodies were also elicited. More detailed analyses revealed that the two mice 
with lower IgG1 antibody titers had higher IgG2a antibody titers and that the mice with 
higher IgG1antibody titers always had lower IgG2a antibody titers. This phenomenon was 
consistent with the influence of cytokines on antibody isotype switching (Table 4.2). 
Nevertheless, each mouse showed high titer of at least one kind of IgG antibody. On the 
other hand, the elicitation of high titers of IgG1 antibody indicated the production of IL-4 
cytokine. 
 
Figure 4.5 ELISA results of antigen-specific antibody isotypes in day 48 antisera of mice 
immunized with: (A) 4.1 plus Titermax Gold adjuvant, (B) 4.2 plus Titermax Gold adjuvant, 
(C) 4.3 plus Titermax Gold adjuvant, respectively. Each dot represents the antibody titer 
of an individual mouse, and the black bar represents the average antibody titer of a group 
of six mice. 
 
Table 4.2 Influence of cytokines on antibody isotype switching16 
Cytokine IgG1 IgG2a IgG2b IgG3 IgM 
IL-4 Induces Inhibits  Inhibits Inhibits 
IFN-γ Inhibits Induces  Induces Inhibits 
TGF-β   Induces Inhibits Inhibits 
 
Previously, we found that KLH-carbohydrate conjugates usually elicited IgG1 
antibodies whereas lipid A-carbohydrate conjugates typically elicited IgG1 and IgG3 
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antibodies.14,17-19 However, the KLH conjugates here elicited various isotypes of IgG 
antibodies. We proposed that different administration routes of vaccines might be one of 
the factors that influence the immune responses. Depending on whether the vaccine is 
administered by s.c. or i.m. injection, the antigen will meet different sets of antigen 
presenting cells (APCs) in the dermal area and in the muscle. As a result, the APCs will 
present the antigenic determinant in MHC-II molecule complex to the T helper cells in the 
nearest local draining lymph nodes which are different as well.20  
Although 4.1-4.3 elicited similar immune responses, the IgG1, IgG2a and IgG3 
antibody titers induced by the higher oligomer 4.3 (pentamer of the RRP repeating unit) 
were significantly lower than that induced by the other two conjugates. Literature results 
also indicated that the trimer and tetramer of the RRP repeating unit showed good 
immunogenicity.11,12 These results combined suggest that the immunogenicity of a poly-
saccharide is not necessarily increased by simply increasing its length. This information 
should be especially useful and helpful for the design and development of fully synthetic 
conjugate vaccines based on oligosaccharide antigens. 
Cross reactions 
To further investigate the properties of antisera induced by different conjugates, 
cross reactions between different antisera and antigens were carried out.  The results are 
shown in Figure 4.6.  
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Figure 4.6 ELISA results of the cross reactions between antigens displayed in 4.4-4.6 
and pooled antisera of mice immunized with 4.1, 4.2 and 4.3. 
 
In this study, the antisera were pooled for each group of 6 mice immunized with 
conjugates 4.1, 4.2 and 4.3, respectively. Conjugates 4.4, 4.5 and 4.6 were used to coat 
plates for ELISA analysis. It is clear that the antisera induced by the three conjugates had 
significant cross reactions, meaning the antibodies induced by each vaccine can at 
different levels recognize and bind the other two oligosaccharide antigens as well. Thus, 
they share some common structural motifs. On the other hand, the reactivities did show 
some differences. In general, antisera showed higher titers to the carbohydrate antigens 
same to the ones in the vaccines used to induce antisera. In addition to the structural 
factor, the loading percent of saccharides in the HSA conjugates and the concentrations 
of antibodies in the antisera may also affect the results shown in Figure 4.6.  This makes 
it complex to derive any firm conclusion.  
Nevertheless, this high level of cross reactions indicated that the structural motif 
of the polysaccharide repeat unit was probably the antigen determinant, and at least a 
part of the antibodies in the antisera were against this common motif. Alternatively, the 
results may be interpreted that the oligosaccharide antigens might have been degraded 
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in vivo, so that antibodies against different lengths of saccharides have been elicited.  In 
the latter case, the antisera induced by 4.3 should show higher cross reactions to 4.4 and 
4.5 than that of 4.1 to 4.5 and 4.6, which is not conclusive. However, degradability of 
vaccines is indeed an important factor influencing vaccine immunity. Usually proteins 
vaccines are digested into pieces by APCs to become suitable for loading onto the MHC 
molecules for presentation to the T cells. However, how carbohydrate antigens are 
processed in the immune system is largely unclear presently. 
 
4.1.3.2 MPLA Conjugates 4.7-4.9 as Vaccines  
Structurally well-defined and characterized conjugates 4.7-4.9 were synthesized 
by Dr. Guochao Liao in the Guo laboratory. Immunological studies of these conjugates 
were performed using female C57BL/6 mice, following the protocols described for 
conjugates 4.1-4.3, except that different vaccine preparations and adjuvant schedules 
were involved. Because MPLA conjugates had low solubility in aqueous buffer, they were 
administered in the form of liposomes, prepared with 1,2-distearoyl-sn-glycero-3-
phosphocholine and cholesterol. According to literature,17,21 this not only can improve the 
solubility of vaccines but also can increase their immunogenicity, as the liposomes may 
help vaccine delivery in vivo. Again, antibody titers were calculated from the logarithm fit 
of the curves of OD value against serum dilution number, and were defined as the dilution 
number yielding an OD value of 0.1.  
Kinetic results of the immune responses 
Experiment to examine the antibody response kinetics against MPLA conjugates 
was performed with 4.7. Thus, 1 day to 9 days after the 5th boost immunization, mouse 
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antisera were obtained and antigen-specific total antibodies were evaluated by ELISA to 
give normalized antibody titers. The results are shown in Figure 4.7. Clearly, 1 day after 
the boot immunization, high titers of antibodies started to appear, and it reached the 
maximum on day 2.  Thereafter, the antibody titers started to decline, and at about day 9, 
the antibody titer became relatively small, even though significant immune response 
remained.  These results demonstrated that the immune responses induced by previous 
immunizations were memorized and immediate and strong immune responses could be 
generated in the mice upon contact of the same antigen. 
 
Figure 4.7. ELISA results of the anti-kappa (total) antibody titers (OD 405 = 0.1) in the 
pooled antisera of mice immunized with conjugate 4.7 obtained on day 1, 2, 4, 5, 7 and 9 
after the 5th boost immunization. 
 
Isotypes of antibodies 
The titers of antibody isotypes in the antisera obtained from mice two days after 
the 5th immunization with 4.7-4.9 were analyzed according to protocols described 
previously. As shown in Figure 4.8, all conjugates induced high titers of IgG3 antibodies, 
which is consistent with the pattern of immune responses to glycolipid conjugates.17,18 In 
the meantime, significant levels of IgG1 and IgG2a antibodies were also observed in the 
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antisera. These results indicated T cell-mediated immune responses, which is important 
for the vaccines. There were some differences in terms of antibody titers among these 
conjugates, but the differences were much less obvious than that observed with KLH 
conjugates 4.1-4.3. Overall, conjugate 4.7 showed the highest IgG antibody, once again 
suggesting that longer saccharides are not necessarily better antigens/immunogens or 
induce stronger immune responses. 
 
Figure 4.8. ELISA results of different isotypes of antigen-specific antibodies in day 2 
antisera of mice after final boost immunization with 4.7, 4.8 and 4.9.  Each dot represents 
the antibody titer of an individual mouse, and the black bar represents the average 
antibody titer of a group of six mice. 
 
Cross reactions 
Figure 4.9 shows the cross reactions of HSA conjugates 4.4-4.6 with all three 
groups of pooled antisera derived from mice immunized with MPLA conjugates 4.7-4.9. 
The results were very similar to that of the KLH conjugates (Figure 4.6). Once again, all 
antisera had significant cross reactions with all three different oligosaccharide antigens, 
suggesting that the three vaccines 4.7-4.9 might share some common antigenic motifs in 
terms of the RRP structure.  
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Figure 4.9 ELISA results of the cross reactions between 4.4-4.6 and the antisera derived 
from mice immunized with 4.7-4.9. 
 
4.1.3.3 Evaluation of the Hib-binding Property of Antisera  
Although we have demonstrated that the synthetic vaccines could induce strong 
antigen-specific immunities, the coating antigens utilized in the ELISA experiments were 
respective oligosaccharides.  The key question is whether the antibodies can recognize 
the carbohydrate antigens on the bacterial cell surface and interact with bacterial cells.  
To answer this question, the cell binding properties of these antisera were evaluated by 
two different experiments. One is the direct binding experiment, which was very similar to 
the regular ELISA except that Hib cells were used as the capture reagents. The other 
experiment was competitive ELSA. For the former experiment, Hib (ATCC 10211) cells 
instead of HSA conjugates were utilized to coat 96-well plates and then pooled mouse 
antisera obtained from mice immunized with conjugate 4.1-4.3 and 4.7-4.9 were added 
to the plates. After washing, AP-linked goat anti-mouse kappa antibody was added for 
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detecting antibodies bound to Hib cell-coated plates, reflected by the OD values at 405 
nm.  The ELISA results are showed on Figure 4.10.  
 
 
Figure 4.10  ELISA results of antibody-Hib binding experiments. (A) and (B): results of 
the 1:100 diluted pooled antisera of conjugates 4.1-4.3 and 4.7-4.9; and (C) and (D): 
results of the 1:300 diluted pooled antisera of 4.1-4.3 and 4.7-4.9 (d0: the pooled sera 
before immunization used as negative controls). The error bars represent standard 
deviations of three parallel experiments. 
 
The pooled antisera before immunization (d0) were used as blank controls which 
had an OD value below 0.2. For the pooled antisera derived from all KLH conjugates, the 
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OD values were similar, ca. 0.85-0.95 (1:100 diluted sera) and 0.6-0.8 (1:300 diluted sera). 
The result confirmed that the antisera against KLH conjugates could successfully 
recognize and bind to Hib cells. For the antisera of MPLA conjugates, at 1:100 dilution, 
significantly higher OD values (0.3-0.5) than that of the d0 antisera were observed, but 
the difference was not significant with 1:300 diluted sera. These results correspond well 
with the observed antibody titers induced by various conjugate vaccines (Figures 4.5 and 
4.8). In conclusion, these results have demonstrated that antisera elicited by KLH and 
MPLA conjugates could bind to Hib cells.  
Competitive ELISA experiment was performed to confirm above antibody binding 
to Hib cells and verify its specificity. The experimental protocols were similar to that for 
regular ELISA except that, in the step of adding diluted antisera solution to coated plates, 
Hib cells were mixed to bind with the antibodies in the antisera solution to compete with 
the HSA-antigen conjugates. The results (Figure 4.11) showed that with the increase of 
Hib cells added to the plate well to compete with HSA conjugates coated in the plates, 
the plate OD values (representing antibodies bound to plates) decreased significantly in 
a concentration dependent manner.  The antisera of two KLH conjugates 4.1-4.3 and 4.7 
had similar results, though it seems that the competition for 4.1 is more effective than the 
others. Therefore, the competitive ELISA results have verified the specific binding of 
antisera obtained from mice immunized with our synthetic vaccines to Hib cells.  
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Figure 4.11. Hib competitive ELISA results using: (A) 1:2700 diluted antisera of mice 
immunized with KLH conjugate 4.1; (B) 1:900 diluted antisera of mice immunized with 
MPLA conjugate 4.7; (C) 1:300 diluted antisera of mice immunized with 4.2; (D) 1:900 
diluted antisera of mice immunized with 4.3. The amounts of Hib cells used in the 
experiments are represented by the OD value (X-axis) of cells at 600 nm, and higher OD 
means higher cell concentrations. Error bars are the standard deviation of three parallel 
experiments. 
 
4.1.4 Conclusions 
In summary, KLH conjugates 4.1-4.3, and MPLA conjugates 4.7-4.9, can elicit 
strong immune response, especially the T cell-mediated immune response. The capbility 
of conjugates to generate antibodies followed the order: 4.1>4.3≈4.2, and 4.7≥4.9>4.8, 
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respectively. Therefore, the Hepta-saccharide had the best results both in KLH conjugate 
and MPLA conjugate. This capability order also suggested that longer saccharides are 
not necessarily better antigens/immunogens or induce stronger immune responses. The 
cross reaction between the three structures was significant which revealed that vaccines 
might share some common antigenic motifs in terms of the RRP structure. The future 
works about this project can focused on the investigation about minimum antigen 
determinant which can provide a principle to direct the design of more effective vaccines. 
To achieve this purpose, the technology of monoclonal antibodies (mAbs) can be 
employed to produce RRP-specific mAb for the study of binding properties with different 
oligomer antigens. This kind of mAb binding studies was well-established in the 
exploration of fungal vaccines by Bundle’s group.22 
 
4.1.4 Experiment Section 
KLH conjugates 
Table 4.3 Doses of KLH conjugates used in animal studies 
Conjugates Loading (%) Each mouse (µg) 6 mice (µg) 6mice 4 times (µg) 
Hepta-KLH 8.4 35.7 214.2 856.8 
Nona-KLH 8.4 35.7 214.2 856.8 
Undecyl-KLH 9.0 33.3 199.8 799.2 
 
All glycoconjugates were synthesized by Dr. Guochao Liao. Titermax Gold 
adjuvant, 1, 2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol were purchased 
from Sigma-Aldrich. Alkaline phosphatase linked goat anti-mouse kappa, IgM, IgG1, 
IgG2a, and IgG3 antibodies and FITC-labeled goat anti-mouse kappa antibody were 
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purchased from Southern Biotechnology. Female C57BL/6J mice of 6-8 weeks age used 
for immunological studies were purchased from the Jackson Laboratory. The doses of 
KLH conjugates were showed in Table 4.3.  
General Procedure for the Preparation of Emulsion of Conjugates 
Each conjugate (30 doses) was dissolved in small 0.3 ml 10× PBS buffer and then 
was diluted to 1.5 ml 2× PBS solution. The solution was mix with 1.5 ml Titermax Gold 
adjuvant (1:1, v/v) and to form an emulsion according to the manufacturer’s protocol. 
(Usually, 1× PBS buffer works well to dissolve the KLH conjugates. However, these 
conjugated are difficultly dissolved in 1× PBS buffer. The high ionic concentration of 10× 
PBS buffer may help the conjugates to dissolve in water-based buffer.)  
Immunization of Mouse  
Each group of six female C57BL/6 mice were immunized on day 1 by 
subcutaneous (sc) injection of 0.1 mL of the emulsion of the conjugate vaccine and 
Titermax Gold adjuvant prepared according to the manufacturer’s protocol. Following the 
initial immunization, mice were boosted 4 times on day 14, day 21, day 28 and day 38 by 
sc injection of the same conjugate and by the same immunization protocol. Blood samples 
of each mouse were collected through the leg veins prior to the initial immunization on 
day 0 and after immunization on day 27, day 38 and d 48 were clotted to obtain antisera 
that were stored at -80 ⁰C before use.  
Protocols for ELISA  
ELISA plates were treated with 100 ul of a solution of individual conjugates (4.4 -
4.6) (2 µg/ml) dissolved in coating buffer (0.1 M bicarbonate, pH 9.6) at 4 ⁰C overnight, 
and then at 37 ⁰C for 1 h, which was followed by treatment with blocking buffer (10% BSA 
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in PBS solution with NaN3) and washing 3 times with phosphate-buffered saline (PBS) 
containing 0.05% Tween-20 (PBST). Thereafter, a pooled or an individual mouse 
antiserum with serial half-log dilutions from 1:300 to 1:656100 in PBS was added to the 
coated ELISA plates (100 µL/well), which was followed by incubation at 37 ⁰C for 2 h. The 
plates were then washed with PBS and incubated at rt for another 1 h with a 1:1000 
diluted solution of alkaline phosphatase linked goat anti-mouse kappa, IgM or IgG2a 
antibody or with a 1:2000 diluted solution of alkaline phosphatase linked goat anti-mouse 
IgG1 and IgG3 antibody (100 µL/well), respectively. Finally, these plates were washed 
with PBS and developed with 100 µL of p-nitrophenylphosphate (PNPP) solution (1.67 
mg/mL in buffer) for 30 min at rt, followed by colorimetric readout using a BioRad 550 
plate reader at 405 nm wavelength. The optical density (OD) values were plotted against 
antiserum dilution values, and a best-fit line was obtained. The equation of the line was 
employed to calculate the dilution value at which an OD of 0.5 was achieved, and the 
antibody titer was calculated at the inverse of the dilution value.  
MPLA conjugates 
4.7 (Hepta-Sacc-MPLA):  MW=2959.22 14.8 μg/mouse, 
4.8 (Nona-Sacc-MPLA):  MW=3305.45 16.53 μg/mouse,  
4.9 (Undecyl-Sacc-MPLA)  MW=3651.68 18.26 μg/mouse,  
Dose: 5.0 ×10-9 mol/mouse, about 9.4 μg saccaride per mouse.  
General Procedure for the Preparation of Liposomes of Glycoconjugates 4.7-4.9.  
The mixture of each specific MPLA conjugate (4.7-4.9) (75.2 μg of saccharide 
moiety, 0.04 μmol), 1, 2-distearoyl-sn-glycero-3-phosphocholine (M.W. 790.15, 200 μg, 
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0.26 μmol), and cholesterol (M.W. 386.66, 77 μg, 0.20 μmol) (a 10:65:50 molar ratio) was 
dissolved in CH2Cl2 and MeOH (1:1, v/v, 2 mL) in a 10 mL vial. Then, the solvents were 
removed in vacuum to form a thin lipid film on the vial wall, which was hydrated by adding 
0.80 mL of HEPES buffer (20 mM, pH 7.5) containing NaCl (150 mM) and was finally 
sonicated for 1 h to obtain the desired liposomes. (This kind of conjugates were difficultly 
dissolved in water-based buffer. So, a long time sonication was need for making milk-like 
liposome form.)  
Immunization of Mouse  
Each group of six female C57BL/6 mice were immunized on day 1 by 
subcutaneous (sc) injection of 0.1 mL of the liposomal solution of a specific 
glycoconjugate 1-3 containing 9.4 μg of the carbohydrate antigen (5.0 nmol) or by 
injection of an emulsion of the liposomal solution of a specific glycoconjugate vaccine. 
Following the initial immunization, mice were boosted 3 times on day 14, day 21 and day 
28 by sc injection of the same conjugate and by the same immunization protocol. Blood 
samples of each mouse were collected through the leg veins prior to the initial 
immunization on day 0 and after immunization on day 27 and day 38 and were clotted to 
obtain antisera that were stored at -80 ⁰C before use.  
The ELISA results of day 27 and day 38 antisera showed that the antibody titer 
was very low which may be caused by that antibody may disappear on day 7 and day 10 
after the boost. The maximum antibody titer may appear on the earlier days after the 
boost. Therefore, the blood was collected again on day 1, 2, 4, 5, 7, and day 9 after 
another boost and the antisera were analyzed.  
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Protocols for ELISA 
ELISA plates were treated with 100 ul of a solution of HSA conjugates 4.4-4.6 (2 
ug/ml) dissolved in coating buffer (0.1 M bicarbonate, pH 9.6) at 4 ⁰C overnight, and then 
at 37 ⁰C for 1 h, which was followed by treatment with blocking buffer (10% BSA in PBS 
solution with NaN3) and washing 3 times with phosphate-buffered saline (PBS) containing 
0.05% Tween-20 (PBST). Thereafter, a pooled or an individual mouse antiserum with 
serial half-log dilutions from 1:300 to 1:656100 in PBS was added to the coated ELISA 
plates (100 uL/well), which was followed by incubation at 37 ⁰C for 2 h. The plates were 
then washed with PBS and incubated at rt for another 1 h with a 1:1000 diluted solution 
of alkaline phosphatase linked goat anti-mouse kappa, IgM or IgG2a antibody or with a 
1:2000 diluted solution of alkaline phosphatase linked goat anti-mouse IgG1 and IgG3 
antibody (100 uL/well), respectively. Finally, these plates were washed with PBS and 
developed with 100 uL of p-nitrophenylphosphate (PNPP) solution (1.67 mg/mL in buffer) 
for 30 min at rt, followed by colorimetric readout using a BioRad 550 plate reader at 405 
nm wavelength. The optical density (OD) values were plotted against antiserum dilution 
values, and a best-fit line was obtained. The equation of the line was employed to 
calculate the dilution value at which an OD of 0.1 was achieved, and the antibody titer 
was calculated at the inverse of the dilution value.  
Protocols for Hib binding ELISA experiments  
Haemophilus influenzae type b (Hib, ATCC 10211) was chose to be performed this 
experiment. Hib was incubated in ATCC #814 agar medium in 37 °C with 5% CO2 
atmosphere for 24 h.  
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Bacterial cells were collected and resuspended in 10% buffered formalin 
phosphate (4% w/w formaldehyde, 0.4% w/w sodium phosphate monobasic monohydrate, 
0.65% w/w sodium phosphate dibasic anhydrous, 1.5% w/w methanol) for 15 min. Then 
the fixed bacteria solution was centrifuged in 1000 rpm for 5 min. The chocolate agar 
medium percipitated in the bottom was removed, and the supernate containing bacterial 
cells was used to coat the 96-well plates. Each well of 96-well plate was coated with 100 
µL bacteria solution which had an OD value of 1 at 600 nm. The 96-well plate was dried 
off under biological cabinet in room temperature and formed a thin bacterial film on the 
bottom of the well.  
The bacteria-coated plate was then treated with BSA blocking buffer (200 µL/well) 
in r.t. for 1 h and then washed three times with PBS containing 0.05% Tween-20 (PBST). 
Then, the pooled antisera from mice immunized with 4.1-4.3 or 4.7-4.9 with dilutions 
1:100 or 1:300 in PBS were added to the coated plate (100 µL/well), respectively, and 
incubated at 37 °C for 2 h. The plates were washed with PBST and incubated at r.t. for 
another one hour with a 1:1000 diluted solution of alkaline phosphate (AP) linked goat 
anti-mouse kappa antibody (100 µL/well). Finally, the plates were washed with PBST and 
developed with 200 µL of a p-nitrophenylphosphate (PNPP) solution (1.67 mg/mL in 
PNPP buffer). After reacting for 30 min at r.t., 100 µL solution obtained from each well 
was used for colorimetric readout using a microplate reader at 405 nm wavelength. OD 
values represented the binding ability of antisera to bacteria.  
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Protocol for Hib Competitive ELISA 
The protocol for this experiment was the same as for regular ELISA described in above 
except that Hib solution (in PBS) was utilized to compete with plate-bound antigen-HSA 
(4.4-4.5) for antibody binding. Thus, after an ELISA plate was treated with different 
antigen-HSA and the blocking solution sequentially and then washed with PBS, 100 µL 
of the pooled antisera obtained from mice immunized with conjugates (1:300, 1:900 or 
1:2700 dilution) in PBS containing different concentration Hib (OD 600 nm value at 0.001, 
0.01, 0.1, and 1) was added to each well of the ELISA plate, respectively. Then, the plate 
was incubated in 37 °C for 2 h and washed. Finally, the plate was treated with alkaline 
phosphatase linked goat anti-mouse kappa antibody (1:1000 dilution), washed, 
developed with PNPP, and finally subjected to colorimetric readout at 405 nm wavelength, 
as described above. 
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4.2 Vaccines against Neisseria Meningitides Serogroup C  
4.2.1 Introduction 
Neisseria meningitides remains a leading cause of bacterial meningitis and 
septicaemia in the United States and other countries.23-26 According their capsular 
polysaccharides, they are classified into 13 serogroups.27,28 In worldwide, most cases of 
meningococcal diseases were caused by serogroup A, B, C, Y and W-135.27 Right now, 
some multivalent polysaccharide vaccines, such as MPSV4 (Menomune; Sanofi-Pasteur, 
1981), ACWY Vax (GlaxoSmithKline) and MCV4 (Menactra; Sanofi Pasteur, 2005), are 
available to provide protection against serogroup A, C, Y and W-135.28  
In 1981, the first meningococcal vaccine, MPSV4 (Menomune; Sanofi Pasteur), 
based on polysaccharides from serogroup A, C, Y and W-135, was licensed in US.26 
However, generally, the polysaccharide vaccines have some marked limitations, such as 
lacking of induction of immunological memory, relatively short duration of protection and 
low immunogenicity in infants.26,29  
To overcome the limitation of low immunological efficiency of vaccines, conjugate 
vaccines in which polysaccharides extracted from Neisseria meningitidis are covalently 
linked to a carrier protein have been developed. Therefore, in 2005, the first such product, 
the quadrivalent meningococcal vaccine MCV4 (Menactra; Sanofi Pasteur) containing 
polysaccharides from N. meningitidis serogroup A, C, Y and W-135 conjugated 
individually to diphtheria toxoid (DT), has been approved in United States.26,29  
The second such product, MenACWY-CRM (Menveo; Novartis Vaccines and 
Diagnostics), another quadrivalent conjugate vaccine, containing N. meningitidis 
serogroup A, C, Y and W-135 oligosaccharides conjugated individually to 
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Corynebacterium diphtheria cross-reactive material (CRM197) was approved by the US 
FDA in 2010, to prevent invasive meningococcal disease in people aged 11-55 years.29,30 
For serogroup B, the polysaccharide of capsular is α[2,8]-linked polysialic acid that 
is identical structure to polysialic acid in fetal neural tissue and therefore may be 
immunotolerated in human immune system.27 One of the general strategy to overcome 
this immunotolerance problem is to modify the carbohydrate antigen to be a foreign 
structure to the host as a vaccine using for immunization. Then the antibody elicited by 
the modified carbohydrate-based vaccine may further cross-react with the natural glycan 
on the pathogen surface. Bruge’s group developed a group B meningococcal vaccine, 
consisting of N-propionylated (NPr) B capsular polysaccharide conjugated to tetanus 
toxoid (TT) carrier protein resulting in moderately higher NPr B polysaccharide-specific 
antibody titers with a certain cross reaction with B polysaccharide antigen.31 However, 
the induced antibodies lack functional activity in vitro. Thus, further investigation about 
this strategy are still needed.  
The other method to develop the vaccine against serogroup B Neisseria 
meningitidis is based on the surface-exposed proteins expressed by the genome 
sequence. Rappuoli’s group and their collaborators developed a total of 350 candidate 
antigens expressed in Escherichia coli, purified and used to immunize mice.32 The surface 
exposed proteins conserved in sequence across a range of strains can induce a 
bactericidal antibody response which may be not only against group B N. meningitidis but 
also against other serogroups and species of pathogenic Neisseria.32  
In conclusion, the above studies have clearly demonstrated that a carbohydrate 
hapten conjugates with a peptide are effective vaccine design against meningitidis. To 
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overcome the immunotolerance of serogroup B N. meningitidis antigen, α[2-8]-linked 
polysialic acids, the vaccines based on modified carbohydrate antigens, or the proteins 
expressed on pathogen surface were explored.  
4.2.2 Our Vaccine Designs 
The previous development of full-synthetic carbohydrate-based vaccines with 
protein carrier or MPLA carrier to against cancer and Hib, encouraged us to develop the 
vaccines against meningitidis based on the capsular polysaccharide antigens of 
serogroup C, α[2-9]-linked polysialic acids. Therefore, our group designed dimer, trimer, 
tetramer and pentamer sialic acids, which were successfully synthesized by Guochao 
Liao, and linked them to KLH and MPLA to form conjugates 4.10-4.13 and 4.18-4.22.  
(Figure 4.12). In the meantime, there oligosaccharides were also coupled with HSA to 
get conjugates 4.14-4.17 that were utilized as the capture reagents in ELISA experiment. 
These new glycoconjugates, 4.10-4.13 and 4.18-4.22 were evaluated as vaccines in mice.  
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Figure 4.12 The structures of designed [α2-9] linked oligo sailic acids KLH conjugates 
(4.10-4.13), HSA conjugates (4.14-4.17), and MPLA conjugates (4.18-4.22)  
 
4.2.3 Results and Discussion 
4.2.3.1 KLH Conjugates 4.10-4.13 as Vaccines 
After the KLH conjugates 4.10-4.13 and HSA conjugates 4.14-4.17 were 
synthesized, their weight% loading of the saccharide moiety were examined by the same 
method described in Hib vaccines, and the results were showed in Table 4.4.  
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Table 4.4 The loading of saccharide moiety in protein conjugates 4.10-4.17 
Conjugates Loading (wt %) 
4.10 (Dimer-KLH) 7.52 
4.11 (Trimer-KLH) 11.49 
4.12 (Tetramer-KLH) 7.89 
4.13 (Pentamer-KLH) 6.83 
4.14 (Dimer-HSA) 8.58 
4.15 (Trimer-HSA) 11.48 
4.16 (Tetramer-HSA) 10.92 
4.17 (Pentamer-HSA) 7.79 
 
Immunological studies of oligo-sialic acid-KLH conjugates (4.10-4.13) were carried 
out with female C57BL/6J mouse. For initial immunizations, each glycolconjugate 
containing 4.7×10-9 mol saccharide residues mixed with Titermax Gold adjuvant as an 
emulsion (0.1 mL) was injected intramuscular (i.m.) in mice (3 µg Dimer-sialic acid moiety 
per mouser, see experiment section). More boost immunization were carried out in these 
mice by subcutaneous (s.c.) injection on day 14, day 21 and day 28, using the same 
vaccines. Each mouse was subjected to bleeding on day 0 before the first injection (used 
as blank controls) and on day 27 and day 38 after immunization. The blood samples were 
treated according to standard protocols to prepare antisera for the analysis of antigen-
specific antibodies by ELISA with the HSA conjugates 4.14-4.17 as capture reagents. In 
addition to total antibodies, antibody isotypes such as IgG1, IgG2a, IgG2b, IgG3 and IgM 
were also individually assessed. Antibody titers were calculated from linear regression 
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analysis of the curves of the optical density (OD) value against the logarithmic scale of 
serum dilution number, and were defined as the dilution number yielding an OD value of 
0.2.  
Figure 4.13 showed the antibody titers of antigen-specific antibodies in d38 
antisera obtained from mice immunized with 4.10-4.13. Each dot represents the antibody 
titer of an individual mouse, and the black bar represents the average antibody titer of a 
group of six mice. The results revealed that all the conjugate 4.10-4.13 can elicit strong 
immune responses, especially the high level of IgG1, IgG2a and IgG2b antibodies 
indicating the involvement of T cell-mediated immunity. In additionally, all the mice had 
similar antibody titer and antibody isotype. The ratio of successful immunization could be 
considered as 100% that means all individual can be successfully provoked to produce 
immune response by the vaccine.  
 
Figure 4.13 ELISA results of antigen-specific antibody isotypes in day 38 antisera of mice 
immunized with (A) 4.10 plus Titermax Gold adjuvant, (B) 4.11 plus Titermax Gold 
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adjuvant, (C) 4.12 plus Titermax Gold adjuvant, (D) 4.13 plus Titermax Gold adjuvant, 
respectively. Each dot represents the antibody titer of an individual mouse, and the black 
bar shows the average antibody titer of a group of five or six mice.   
 
In all the isotypes, IgG2b was extremely higher than the other isotype for all the six 
mice. According Table 4.2, it indicated that TGF-β cytokine was involved in this immune 
response. The IgG1 was also showed good antibody titers which may indicated that IL-4 
cytokines was involved. The corresponding T cell immune pathway can be figure out 
according this relationship between cytokines and antibody isotype switching (Table 
4.2).16 Falk Nimmerjahn and Jeffrey V. Ravetch33 found out that different isotype of IgG 
can bind to different Fcγ receptors which included activation and inhibitory receptors. 
Based on the activating-to-inhibitory (A/I) ratio of the receptors IgG binding to, the 
hierarchy of activity for the IgG subclasses was thus IgG2a≥IgG2b>IgG1>>IgG3.33 
Therefore, in this result, the high antibody titer of IgG2b elicited by the vaccines could be 
considered that antibody IgG2b has very strong immune activities.  
Furthermore, among IgG subclasses, IgG 2a and 2b are generally considered to 
be the most potent for activating effector responses and dominate antiviral immunity, 
which also supported the application potential of this anti-bacteria vaccine.34-38  
In another aspect, carrier protein KLH should make an important role in IgG isotype 
switch because that protein antigens usually elicit a thymus-dependent response 
generally represented by the IgG1, 2a and 2b, whereas carbohydrate antigens can elicit 
thymus-independent responses that induce IgG3 antibody secretion.39 Hence, in the 
carbohydrate antigen vaccine, carrier protein was very important to improve the 
immunogenicity. Moreover, the adjuvant, Titermax Golden adjuvant, worked well with 
poly-sialic acids KLH conjugates.  
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Kappa antibody isotype standing for the total antibodies, and IgG2b isotype 
representing T cell-mediated immunity, were selected to compare the immunogenicity of 
conjugates (Figure 4.14). There was no statistical difference between group Dimer 4.10 
and Trimer 4.11. Interestingly, the kappa antibody titers induced by the higher oligomer 
(4.12 and 4.13) were significantly lower than that induced by 4.11, but the IgG2b antibody 
titers were almost the same for all the conjugates. The saccharide loading of HSA 
conjugates was closed to each other which may hardly affect the antibody titers. Hence, 
the trend of kappa antibody titer may due to the immunogenicity of oligo-sialic acids 
antigen only. Therefore, the capability of conjugates to generate the kappa antibodies 
followed the order 4.11≈4.10>4.12≈4.13, while the capability to generate IgG2b was 
similar.  
 
Figure 4.14 The antigen-specific antibody titers of kappa (A and B) and IgG2b (C and D) 
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isotypes for all the four glycoconjugates 4.10-4.13. In (A) and (C), each dot represents 
the antibody titer of an individual mouse, and the black bar shows the average antibody 
titer of a group of five or six mice. In (B) and (D), the error bar represented the standard 
deviation of six or five individual mice. 
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Figure 4.15 The kinetic plot of glycoconjugates (4.10-4.13). The pooled antisera of day 
28 was obtained from mice immunized three times with glycoconjugates, respectively. 
The pooled antisera of day 38 was obtained ten days later after the fourth boost from the 
mice immunized with glycoconjugates, respectively.  
 
For all the four groups, antibody titer of kappa on day 38 was slightly higher than 
day 28. After third or fourth administration, the antibody titer had already reached a high 
level which indicated that three or four times injection was sufficient for the immunization.  
 
Cross reaction 
To further investigate the properties of antisera induced by different conjugates, 
cross reactions between different antisera and antigens were carried out. The protocol of 
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cross reaction was similar as that in anti-Hib vaccines. The results are shown in Figure 
4.16.  
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Figure 4.16 The ELISA results of cross reactions between the pooled antisera obtained 
from mice immunized with conjugates (4.10-4.13) dimer-, trimer-, tetramer- and 
pentamer-sialic acid-KLH and the capture reagents (4.14-4.17) dimer-, trimer-, tetramer- 
and pentamer-sialic acid-HSA.  
 
It is clear that the antisera induced by the four conjugates had significant cross 
reactions, meaning the antibodies induced by each vaccine can recognize and bind the 
other oligosaccharide antigens as well. Thus, they share some common structural motifs 
that should be dimer-sialic acid. This high level of cross reactions indicated that the 
structural motif of dimer-sialic acid was probably the minimum antigen determinant, and 
at least a part of the antibodies in the antisera were against this common motif.  
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4.2.3.2 MPLA Conjugates 4.18-4.22 as Vaccines 
The MPLA conjugates 4.18-4.22, as structural well-defined and characterized 
constructs, were synthesized by Dr. Guochao Liao in our laboratory. Immunological 
studies of these conjugates were performed using female C57BL/6J mice, following the 
similar protocols described for anti-Hib MPLA conjugates 4.7-4.9.  
All the conjugates 4.18-4.22 were incorporated in liposomes formed by using 1,2-
distearoyl-sn-glycero-3-phosphocholine and cholesterol to improve the solubility in buffer 
and further improve the immunogenicity. For immunization, the liposomal preparations of 
conjugate 4.18-4.22 were each injected subcutaneously (s.c.) to a group of five or six 
mice. Each female C57BL/6J mouse was injected with 0.1 mL of a vaccine preparation 
containing ca. 14.0 nmol of saccharide moiety on day 1, 14, 21 and 28, respectively. Each 
mouse was subjected to bleeding on day 0 before the first injection (used as blank 
controls) and on day 27 and 35 after immunization. The blood samples were treated 
according to standard protocols to prepare antisera for the analysis of antigen-specific 
antibodies by ELISA with the HSA conjugates (4.14-4.17) as capture antigens. In addition 
to total antibodies, antibody isotypes including IgG1, IgG2a, IgG2b, IgG3 and IgM were 
also individually analyzed. Antibody titers were calculated from linear regression analysis 
of the curves of the optical density (OD) value against logarithmic scale of serum dilution 
number, and were defined as the dilution number yielding an OD value of 0.2.  
Isotypes of antibodies 
Figure 4.17 shows the isotypes of antibodies in the antisera obtained from mice 
immunized with conjugate 4.18-4.22.  
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Figure 4.17 The ELISA results of antigen-specific antibody titers in day 35 antisera of 
mice immunized with (A) 4.18 alone, (B) 4.18 plus Freund’s Completed Adjuvant (CFA), 
(C) 4.19 alone, (D) 4.20 alone, (E) 4.21 alone and (F) 4.22 alone, respectively. Each dot 
represents the antibody titer of an individual mouse, and the black bar shows the average 
antibody titer of a group of five or six mice.  
 
The ELISA results of antibody titers in antisera obtained with 4.18-4.22 without the 
use of an external adjuvant (Figure 4.17 except (B)) suggested that all the conjugates 
provoked a strong antigen-specific immune response in mice. Moreover, the high 
antibody titer of IgG2b isotype and some IgG1 and IgG3 antibody isotypes revealed that 
a T cell-dependent immune response was involved.17,18 According to previous discussion, 
IgG2b has an extremely high immunological activity which further confirmed that this 
conjugate had strong immunogenicity and could be further developed to be a 
vaccine.33,37,38 In addition, no significant difference between the antisera obtained from 
mice immunized with conjugate 4.18 alone and plus CFA adjuvant either in kappa or in 
IgG isotypes. This result confirmed the great adjuvant function of MPLA as a build-in 
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carrier and the possibility of adjuvant-free vaccine preparations.17,18  
Tetramer-sialic acid saccharide was conjugated with two kinds of MPLA including 
the best one we optimized in chapter 3 and another one without two hydroxyl groups in 
the acetyl-chains (Figure 4.12).18 The ELISA results of antisera obtained from mice 
immunized with 4.20 and 4.22 indicated that both the conjugates can provoke strong 
immune response in mice. However, the antibody titers of antisera obtained with 4.20 
were significantly higher than that of 4.22 which revealed that the MPLA structure without 
two hydroxyl groups had much lower immunostimulatory ability.17,40 In another aspect, 
this result confirmed that MPLA as a build-in adjuvant and as a carrier played an 
extremely important role in the immunostimulatory pathway that even a small change in 
the MPLA structure can induced a significant decrease in the final antibody production. 
To enhance the immunogenicity of MPLA conjugates, the optimized structure was the 
best choice for vaccine design.  
The ELISA results of antisera obtained from mice immunized with conjugate 4.21 
were interesting that the total antibody titer was significantly decreased but the antibody 
titer of IgG2b isotype was almost the same as the other conjugates. The phenomenon 
was similar as that in KLH conjugates. This means that the pentamer-sialic acid-MPLA 
conjugate may have a comparable potential to be designed as a vaccine.  
In conclusion, all these conjugates without external adjuvant can elicit strong 
immune response, especially the T cell-dependent immunity. The MPLA as a build-in 
adjuvant and a carrier plays an extremely important role in the immunostimulatory 
pathway although the details of antibody production and antibody isotype switching were 
not clear. Moreover, with the length of saccharide moiety increasing, the total antibody 
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titer was decreased slightly but the antibody titer of IgG2b isotype was consistent.  
Cross Reaction 
To investigate the recognition pattern of provoked antibodies, the cross reactions 
between different length saccharides and the antisera obtained from mice immunized with 
different saccharides conjugates were carried out (Figure 4.18). Antisera of 4.18 had the 
highest antibody titer with Dimer-sialic acid-HSA, but had a significant lower cross 
reactivity with longer sialic acid-HSA. This phenomenon revealed that, although dimer-
sialic acid did induce anti-dimer antibodies, these antibodies may be not protective due 
to the low reactivity with other oligomer antigens which should be more popular on 
bacteria surface. However, the cross reactivity of other conjugates (4.19-4.22) were 
strong and similar as that in KLH conjugates (4.10-4.13).  
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Figure 4.18 The ELISA results of cross reactivity of the antisera induced by conjugates 
(4.18-4.22) dimer-, trimer-, tetramer- and pentamer-sialic acid-MPLA and the different 
capture reagents (4.14-4.17) from dimer- to pentamer-sialic acid-HSA.  
 
The antibodies elicited by vaccines should be more effective if they can cross react 
with wild-spectrum oligosaccharide antigens. Thus the proper number of oligomer in this 
kind vaccine construct should be higher than 2. Combining with the conclusion in above 
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isotype discussion, trimer-sialic acid conjugates was the best design with best capability 
to generate effective antibodies. The cross reactivity was an important topic and worth to 
be further investigated.  
 
4.2.4 Conclusion 
In summary, all the oligo-sialic acid-KLH and -MPLA conjugates can stimulate 
extremely strong immune response, especially high level of IgG2b antibody titer which 
indicated T cell-dependent immunity successfully involving. The IgG2b considered as one 
of the most powerful antibody isotypes was particularly concentrated. In each group, all 
five or six mice can be successfully immunized. Among these conjugates, trimer-sialic 
acid was the best candidate for both KLH and MPLA constructs. Dimer-sialic acid may be 
too short for a protective vaccine because the low cross reactivity of antibodies. The 
results of MPLA conjugates further confirmed the potential immunostimulatory ability of 
MPLA which can be developed to be an efficient carrier and build-in adjuvant. In future 
works, the deeply investigation of structure-activity relationships of oligo-sialic acid 
antigens should be an interesting and meaningful direction. For this purpose, the 
monoclonal antibodies (mAb) can be prepared and the interactions of mAb and oligomer 
antigens can be further explored by NMR binding studies.22  
 
4.2.5 Experiment Section 
Materials, reagents and animals 
All glycoconjugates were synthesized by Dr. Guochao Liao. Titermax Gold 
adjuvant, 1, 2-distearoyl-sn-glycero-3-phosphocholine, and cholesterol were purchased 
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from Sigma-Aldrich. Alkaline phosphatase linked goat anti-mouse kappa, IgM, IgG1, 
IgG2a, and IgG3 antibodies and FITC-labeled goat anti-mouse kappa antibody were 
purchased from Southern Biotechnology. Female C57BL/6J mice of 6-8 weeks age used 
for immunological studies were purchased from the Jackson Laboratory. 
N.M group C vaccine poly-sialic acid-KLH conjugate: 
Saccharide about 4.66×10-9 mol per mouse (3 µg Dimer-sialic acid moiety per 
mouse per time to scale up). The loading percentages are shown in Table 4.4 above.  
Table 4.5 Dose of each KLH conjugate (4.10-4.13) used for immunizing mice 
Dose Saccharide/µg Conjugates/µg 24 doses/µg 30 doses/mg 
Dimer (4.10) 3.00 39.89 957.36 1.1967 
Trimer (4.11) 4.35 37.89 909.36 1.1367 
Tetramer (4.12) 5.71 72.376 1737 2.171 
Pentamer (4.13) 7.07 103.47 2483 3.104 
 
N.M group C vaccine poly-sialic acids-MPLA conjugates:  
13.98×10-9 mol (9 µg dimer sialic acid moiety, 33.59 µg conjugate) per mouse  
Table 4.6 Dose of each MPLA conjugate (4.18-4.22) used for immunizing mice 
Dose nmol M.W. 1 dose/ug 30 doses/ug 
Dimer (4.18) 13.98 2402.9432 33.59 1.007 
Trimer (4.19) 13.98 2694.1978 37.66 1.1298 
Tetramer 1 (4.20) 13.98 2985.4523 41.736 1.2521 
Tetramer 2(4.22) 13.98 2953.4535 45.81 1.239 
Pentamer (4.21) 13.98 3276.7069 41.29 1.3743 
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General Procedure for the Preparation of Emulsion of KLH Conjugates 
Each conjugate (30 doses, 1.19 mg of 4.10, 1.14 mg of 4.11, and 2.17 mg of 4.12, 
and 3.10 mg of 4.13, respectively) was dissolved in 1.5 ml 1× phosphate-buffered saline 
(PBS) buffer. The solution was mix with 1.5 ml Titermax Gold adjuvant (1:1, v/v) and to 
form an emulsion according to the manufacturer’s protocol.  
General Procedure for the Preparation of Liposomes of MPLA Glycoconjugates  
The mixture of a specific MPLA conjugate (4.18-4.22) (13.98 nmol for each dose), 
1, 2-distearoyl-sn-glycero-3-phosphocholine (M.W. 790.15), and cholesterol (M.W. 
386.66) (a 10:65:50 molar ratio) was dissolved in CH2Cl2 and MeOH (1:1, v/v, 2 mL) in a 
10 mL vial. Then, the solvents were removed in vacuum to form a thin lipid film on the vial 
wall, which was hydrated by adding 2.0 mL of HEPES buffer (20 mM, pH 7.5) containing 
NaCl (150 mM) and shaking the mixture in 40 ⁰C water bath, and then shaking it by vortex 
mixer for several times to form a milky suspension. The milky suspension was finally 
sonicated for 1 min to obtain the desired liposomes.  
The liposome of MPLA conjugates with double concentration of the front one, was 
mixed with the same volume of Completed Freud’s adjuvant (CFA) to form a uniform 
formula according to the manufacturer’s protocol.  
Immunization of Mouse  
For KLH conjugates: Each female C57BL/6J mice in a group of six was immunized on 
day 1 by intramuscular (i.m.) injection of 0.1 mL of the emulsion of the conjugate vaccine 
and adjuvant prepared according to the manufacturer’s protocol. Following the initial 
immunization, mice were boosted 3 times on day 14, day 21, and day 28 by subcutaneous 
(sc.) injection of the same conjugate prepared by the same protocol. Blood samples of 
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each mouse were collected through the leg veins prior to the initial immunization on day 
0 and after immunization on day 28 and d 38 were clotted to obtain antisera that were 
stored at -80 ⁰C before use.  
For lipid A conjugates: Each female C57BL/6J mice in a group of six was immunized 
on day 1 by subcutaneous (sc.) injection of 0.1 mL of the liposome of the conjugate 
vaccine with/without adjuvant prepared according to the manufacturer’s protocol. 
Following the initial immunization, mice were boosted 3 times on day 14, day 21, and day 
28 by subcutaneous (sc.) injection of the same conjugate prepared by the same protocol. 
Blood samples of each mouse were collected through the leg veins prior to the initial 
immunization on day 0 and after immunization on day 18, day 28 and d 35 were clotted 
to obtain antisera that were stored at -80 ⁰C before use.  
Protocols for ELISA 
ELISA plates were treated with 100 ul of a solution of HAS conjugate (2 ug/ml) 
dissolved in coating buffer (0.1 M bicarbonate, pH 9.6) at 4 ⁰C overnight, and then at 37 
⁰C for 1 h, which was followed by treatment with blocking buffer (10% BSA in PBS solution 
with NaN3) and washing 3 times with phosphate-buffered saline (PBS) containing 0.05% 
Tween-20 (PBST). Thereafter, a pooled or an individual mouse antiserum with serial half-
log dilutions from 1:300 to 1:656100 in PBS was added to the coated ELISA plates (100 
uL/well), which was followed by incubation at 37 ⁰C for 2 h. The plates were then washed 
with PBS and incubated at rt for another 1 h with a 1:1000 diluted solution of alkaline 
phosphatase linked goat anti-mouse kappa, IgM, IgG2a and IgG2b antibody or with a 
1:2000 diluted solution of alkaline phosphatase linked goat anti-mouse IgG1 and IgG3 
antibody (100 uL/well), respectively. Finally, these plates were washed with PBS and 
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developed with 100 uL of p-nitrophenylphosphate (PNPP) solution (1.67 mg/mL in buffer) 
for 30 min at rt, followed by colorimetric readout using a BioRad 550 plate reader at 405 
nm wavelength. The optical density (OD) values were plotted against antiserum dilution 
values, and a best-fit line was obtained. The equation of the line was employed to 
calculate the dilution value at which an OD of 0.2 was achieved, and the antibody titer 
was calculated at the inverse of the dilution value. 
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The unique carbohydrates expressed on the surface of cancer, bacterial, viral 
and fungal cells are excellent target antigens for the design of therapeutic or preventive 
vaccines. However, as antigens carbohydrates have problems. First, carbohydrates 
usually have low immunogenicity. Second, even if immunogenic, carbohydrates typically 
elicit T cell-independent immune responses. To overcome these problems and design 
useful vaccines based on carbohydrate antigens, they are usually coupled with carrier 
proteins to form conjugates to enhance the immunogenicity of the antigens. However, 
there are still some issues existing in glycoprotein vaccines, such as poor reproducibility 
of the conjugates, difficulties in quality control and so on. To deal with these issues, our 
group explored a strategy to utilize synthetic carbohydrate antigens with well-defined 
structures for the construction of glycoprotein vaccines. In the meantime, our group has 
also developed new vaccine carriers, such as monophosphoryl lipid A (MPLA), to 
construct full-synthetic carbohydrate-based vaccines that have well-defined structures 
and improved immunological properties. The main aims of this dissertation are to study 
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and evaluate these semi- and full-synthetic glycoconjugates and develop carbohydrate-
based vaccines against cancer and bacteria.  
The first part of this dissertation (Chapters 2 and 3) is focused on antitumor 
vaccines targeting at tumor-associated carbohydrate antigens (TACAs). For TACAs, in 
addition to the problems associated with carbohydrate antigens mentioned above, there 
is another problem, namely immunotolerance, due to their structural similarity to normal 
carbohydrates on normal cells. To overcome the immunotolerance problem, our group 
developed a novel immunotherapeutic strategy based on glycoengineering of sialo-
TACAs on cancer cells. An important requirement for this strategy to work is to engineer 
cancer cells to express unnatural sialo-TACAs. In Chapter 2, a convenient method was 
developed for the quantification of various sialic acids expressed by cells and used to 
analyze the efficiency of N-phenylacetyl-D-mannosamine (ManNPhAc) to metabolically 
glycoengineer SKMEL-28 cancer cell. In specific, after cancer cells were cultured with 
ManNPhAc, the cells were treated with 2M acetic acid to release sialic acids and then 
with 1,2-diamino-4,5-methylenedioxybenzene (DMB). Sialic acids could react with DMB 
to form the corresponding derivatives that had strong UV absorptions. The reaction 
mixture was then applied to HPLC-UV analysis to determine the amounts and the ratios 
of natural sialic acid and its unnatural analog. It was confirmed that after incubation with 
ManNPhAc, the SKMEL-28 cell was effectively glycoengineered to express a significant 
amount of unnatural sialic acid.  
Another requirement for the new cancer immunotherapeutic strategy is to have 
effective vaccines made of TACAs that contain the correspondingly modified sialic acid. 
In Chapter 3, a new construct of carbohydrate-based cancer vaccines with MPLA as the 
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carrier molecule and a build-in adjuvant, which are full-synthetic and potentially possess 
strong and self-adjuvanting immunological activities, were investigated. For this purpose, 
four MPLA analogs were prepared and immunologically evaluated to identify the ideal 
vaccine carrier. It was confirmed MPLA conjugates of chemically modified sTn antigen 
induced robust immune responses, thus they can be used as effective vaccines for the 
new cancer immunotherapeutic strategy. Furthermore, the optimized MPLA was used to 
develop Globo H-based anti-breast cancer vaccine. The immunological results of Globo 
H-keyhole limpet hemocyanin (KLH) and Globo H-MPLA conjugates indicated that the 
Globo H-MPLA conjugate had better immunogenicity than that of Globo H-KLH, 
including the capability of stimulating a T cell-mediated immunity. Therefore, Globo H-
MPLA had the potential for being further developed into clinically useful vaccines.  
The second part of this dissertation (Chapter 4) is focused on the development of 
antibacterial vaccines based on their capsular polysaccharide antigens. Instead of using 
polysaccharides isolated from bacterial cells, oligomers of the polysaccharide antigen 
repeating units were synthesized and then conjugated with a carrier protein, such KLH, 
or a MPLA derivative to form semi- or full-synthetic vaccines. The resultant conjugates 
were evaluated in mice and their structure-activity relationships were analyzed to 
identify the proper repeating unit oligomers for vaccine development. In this dissertation, 
two types of bacteria Haemophilus Influenzae type b (Hib) and group C Neisseria 
meningitidis were studied. The target antigen for Hib was the repeating ribosylribitol 
phosphate (RRP) polysaccharide, and for group C N. meningitides, the target antigen 
was α[2,9]-linked polysialic acid. Immunological studies of these conjugates suggested 
that they all can stimulate strong T-cell mediated immune responses. Most importantly, 
144 
 
it was concluded that short oligomers of bacterial polysaccharide antigens can be highly 
immunogenic and induce immune responses that can recognize and bind the target 
pathogens. 
In conclusion, in this dissertation, a new method was developed for quantitative 
analysis of cell surface sialic acids and analysis of the efficiency of sialic acid metabolic 
engineering. This method can be broadly useful for various cells and sialic acid analogs. 
In this dissertation, two different vaccine strategies, which could lead to semi- and fully 
synthetic vaccines, against cancer and bacteria have been investigated in great details.  
These vaccines showed promising properties and are worth further investigation.  More 
importantly, the results of this dissertation have provided proof of principle for the new 
strategies, which may be widely applicable to other cancer and bacteria.  
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